Dirk Jan Van Veldhuisen

Dirk Jan Van Veldhuisen's AcademicInfluence.com Rankings

Medical

#1084

World Rank

#1382

Historical Rank

Cardiology

#66

World Rank

#67

Historical Rank

medical Degrees

Download Badge

Medical

Dirk Jan Van Veldhuisen's Degrees

Doctorate Medicine University of Groningen
PhD Cardiology University of Groningen

Why Is Dirk Jan Van Veldhuisen Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Dirk Jan Van Veldhuisen's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

2015 ESC Guidelines for the Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. (2016) (2621)
Eplerenone in patients with systolic heart failure and mild symptoms. (2011) (2505)
Urinary Albumin Excretion Predicts Cardiovascular and Noncardiovascular Mortality in General Population (2002) (1585)
Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). (2005) (1481)
Targeted Anticytokine Therapy in Patients With Chronic Heart Failure: Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL) (2004) (1127)
Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. (2019) (1066)
Prognostic Association of Depression Following Myocardial Infarction With Mortality and Cardiovascular Events: A Meta-analysis (2004) (1049)
Renal function, neurohormonal activation, and survival in patients with chronic heart failure. (2000) (1032)
Rosuvastatin in older patients with systolic heart failure. (2007) (905)
Renal Function as a Predictor of Outcome in a Broad Spectrum of Patients With Heart Failure (2006) (859)
Lenient versus strict rate control in patients with atrial fibrillation. (2010) (856)
Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency† (2014) (837)
Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease. (2009) (794)
[2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death]. (2015) (729)
Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. (2014) (704)
Anemia and mortality in heart failure patients a systematic review and meta-analysis. (2008) (650)
Effects of Fosinopril and Pravastatin on Cardiovascular Events in Subjects With Microalbuminuria (2004) (564)
Worsening renal function and prognosis in heart failure: systematic review and meta-analysis. (2007) (562)
Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. (2007) (547)
Effect of moderate or intensive disease management program on outcome in patients with heart failure: Coordinating Study Evaluating Outcomes of Advising and Counseling in Heart Failure (COACH). (2008) (542)
Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction (2010) (539)
Outcome of pregnancy in women with congenital heart disease: a literature review. (2007) (532)
Compliance in heart failure patients: the importance of knowledge and beliefs. (2006) (530)
Iron deficiency in chronic heart failure: an international pooled analysis. (2013) (519)
Predictors of pregnancy complications in women with congenital heart disease. (2010) (484)
Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. (2000) (465)
Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). (2009) (449)
Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND. (2013) (445)
Treatment of anemia with darbepoetin alfa in systolic heart failure. (2013) (439)
Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study (2010) (411)
Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology (2018) (402)
Intrathoracic Impedance Monitoring, Audible Patient Alerts, and Outcome in Patients With Heart Failure (2011) (399)
Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. (2005) (393)
Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin–angiotensin–aldosterone inhibitors (2020) (379)
Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. (2007) (378)
Genetic and Pharmacological Inhibition of Galectin-3 Prevents Cardiac Remodeling by Interfering With Myocardial Fibrogenesis (2013) (377)
B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction. (2013) (375)
Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials (2018) (372)
Common variants in 22 loci are associated with QRS duration and cardiac ventricular conduction (2010) (345)
The fibrosis marker galectin‐3 and outcome in the general population (2012) (343)
Effect on Survival and Hospitalization of Initiating Treatment for Chronic Heart Failure With Bisoprolol Followed by Enalapril, as Compared With the Opposite Sequence: Results of the Randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III (2005) (328)
Drawbacks and Prognostic Value of Formulas Estimating Renal Function in Patients With Chronic Heart Failure and Systolic Dysfunction (2006) (312)
Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron‐deficient heart failure patients: an individual patient data meta‐analysis (2018) (289)
Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study (2017) (288)
Symptom dimensions of depression following myocardial infarction and their relationship with somatic health status and cardiovascular prognosis. (2006) (282)
Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. (2006) (278)
Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction. (2005) (271)
Telomere length of circulating leukocytes is decreased in patients with chronic heart failure. (2006) (269)
Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial. (2015) (266)
Diuretic response in acute heart failure: clinical characteristics and prognostic significance. (2013) (263)
Genetic association study of QT interval highlights role for calcium signaling pathways in myocardial repolarization (2014) (260)
Prognostic value of the presence and development of atrial fibrillation in patients with advanced chronic heart failure. (2000) (257)
Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study. (2012) (257)
Vagus Nerve Stimulation for the Treatment of Heart Failure: The INOVATE-HF Trial. (2016) (255)
Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Chronic Heart Failure and Iron Deficiency (2017) (255)
Cardiovascular toxicity caused by cancer treatment: strategies for early detection. (2009) (254)
Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial. (2017) (252)
Effect of Ularitide on Cardiovascular Mortality in Acute Heart Failure (2017) (248)
Prognostic utility of plasma neutrophil gelatinase-associated lipocalin in patients with acute heart failure: The NGAL EvaLuation Along with B-type NaTriuretic Peptide in acutely decompensated heart failure (GALLANT) trial (2011) (248)
Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial. (2010) (246)
Regional myocardial blood flow reserve impairment and metabolic changes suggesting myocardial ischemia in patients with idiopathic dilated cardiomyopathy. (2000) (243)
Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease (2018) (238)
The European cardiac resynchronization therapy survey. (2009) (237)
The Importance and Impact of Social Support on Outcomes in Patients With Heart Failure: An Overview of the Literature (2005) (235)
Eplerenone in Patients With Systolic Heart Failure and Mild Symptoms: Analysis of Repeat Hospitalizations (2012) (234)
Heart Failure With Preserved Ejection Fraction and Atrial Fibrillation: Vicious Twins. (2016) (234)
Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovascularization. (2007) (230)
Abnormal liver function in relation to hemodynamic profile in heart failure patients. (2010) (227)
Myocardial strain and torsion quantified by cardiovascular magnetic resonance tissue tagging: studies in normal and impaired left ventricular function. (2006) (226)
Galectin-3 in Cardiac Remodeling and Heart Failure (2010) (220)
Mechanisms of atrial structural changes caused by stretch occurring before and during early atrial fibrillation. (2011) (220)
C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study. (2009) (219)
Heart failure with preserved ejection fraction: from mechanisms to therapies (2018) (215)
Peripartum Cardiomyopathy as a Part of Familial Dilated Cardiomyopathy (2010) (215)
Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure). (2009) (210)
Increased brain and atrial natriuretic peptides in patients with chronic right ventricular pressure overload: correlation between plasma neurohormones and right ventricular dysfunction (2001) (207)
Renal function: the Cinderella of cardiovascular risk profile. (2001) (204)
Tubular damage in chronic systolic heart failure is associated with reduced survival independent of glomerular filtration rate (2010) (203)
Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01). (2014) (202)
Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure). (2013) (201)
Compliance with non-pharmacological recommendations and outcome in heart failure patients. (2010) (199)
Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients. (2001) (199)
Gender-related differences in rhythm control treatment in persistent atrial fibrillation: data of the Rate Control Versus Electrical Cardioversion (RACE) study. (2005) (198)
Comparison Between the Prognostic Value of Left Ventricular Function and Myocardial Perfusion Reserve in Patients with Ischemic Heart Disease (2009) (195)
Comparison between New York Heart Association classification and peak oxygen consumption in the assessment of functional status and prognosis in patients with mild to moderate chronic congestive heart failure secondary to either ischemic or idiopathic dilated cardiomyopathy. (1992) (192)
Prognostic Value of Changes in Galectin-3 Levels Over Time in Patients With Heart Failure: Data From CORONA and COACH (2013) (191)
Right heart dysfunction and failure in heart failure with preserved ejection fraction: mechanisms and management. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology (2018) (191)
Lack of evidence of increased mortality among patients with atrial fibrillation taking digoxin: findings from post hoc propensity-matched analysis of the AFFIRM trial. (2013) (189)
Prognostic value of plasma erythropoietin on mortality in patients with chronic heart failure. (2004) (187)
Contemporary Use of Digoxin in the Management of Cardiovascular Disorders (2006) (187)
Iron deficiency impairs contractility of human cardiomyocytes through decreased mitochondrial function (2018) (185)
Protective effects of erythropoietin in cardiac ischemia: from bench to bedside. (2006) (185)
Do Self-Management Interventions Work in Patients With Heart Failure?: An Individual Patient Data Meta-Analysis (2016) (183)
Prognostic value of heart rate variability during long-term follow-up in patients with mild to moderate heart failure. The Dutch Ibopamine Multicenter Trial Study Group. (1996) (182)
Sodium–glucose co‐transporter 2 inhibition with empagliflozin improves cardiac function in non‐diabetic rats with left ventricular dysfunction after myocardial infarction (2019) (181)
Targeted therapy of underlying conditions improves sinus rhythm maintenance in patients with persistent atrial fibrillation: results of the RACE 3 trial (2018) (178)
Timing of Erythropoietin Treatment for Cardioprotection in Ischemia/Reperfusion (2004) (178)
Rate control versus rhythm control for patients with persistent atrial fibrillation with mild to moderate heart failure: results from the RAte Control versus Electrical cardioversion (RACE) study. (2005) (176)
Clinical outcome of renal tubular damage in chronic heart failure. (2011) (176)
Accelerated decline and prognostic impact of renal function after myocardial infarction and the benefits of ACE inhibition: the CATS randomized trial. (2003) (176)
Development and validation of multivariable models to predict mortality and hospitalization in patients with heart failure (2017) (175)
Heart Rate and Rhythm and the Benefit of Beta-Blockers in Patients With Heart Failure. (2017) (174)
Prospective validation and assessment of cardiovascular and offspring risk models for pregnant women with congenital heart disease (2014) (173)
Quality of life and depressive symptoms in the elderly: a comparison between patients with heart failure and age- and gender-matched community controls. (2009) (170)
Identifying Pathophysiological Mechanisms in Heart Failure With Reduced Versus Preserved Ejection Fraction. (2018) (167)
Heart Failure Stimulates Tumor Growth by Circulating Factors (2018) (167)
Right ventricular dysfunction in heart failure with preserved ejection fraction: a systematic review and meta‐analysis (2016) (166)
Double-blind placebo-controlled study of ibopamine and digoxin in patients with mild to moderate heart failure: results of the Dutch Ibopamine Multicenter Trial (DIMT). (1993) (164)
Secondary prevention with folic acid: effects on clinical outcomes. (2003) (162)
Titin gene mutations are common in families with both peripartum cardiomyopathy and dilated cardiomyopathy. (2014) (161)
Pregnancy and delivery in women after Fontan palliation (2006) (155)
Anaemia in chronic heart failure is not only related to impaired renal perfusion and blunted erythropoietin production, but to fluid retention as well. (2006) (153)
Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). (2012) (152)
Signature of circulating microRNAs in patients with acute heart failure (2016) (152)
Levels of Hematopoiesis Inhibitor N-Acetyl-Seryl-Aspartyl-Lysyl-Proline Partially Explain the Occurrence of Anemia in Heart Failure (2005) (151)
Increased Brain Natriuretic Peptide as a Marker for Right Ventricular Dysfunction in Acute Pulmonary Embolism (2001) (151)
Biomarker Profiles in Heart Failure Patients With Preserved and Reduced Ejection Fraction (2017) (150)
High yield of LMNA mutations in patients with dilated cardiomyopathy and/or conduction disease referred to cardiogenetics outpatient clinics. (2007) (150)
Erythropoietin in cardiovascular diseases. (2004) (149)
Rationale and study design of the increase of vagal tone in heart failure study: INOVATE-HF. (2012) (149)
Added value of a physician-and-nurse-directed heart failure clinic: results from the Deventer–Alkmaar heart failure study (2006) (147)
Detection of anthracycline-induced cardiotoxicity. (1999) (145)
A single dose of erythropoietin in ST-elevation myocardial infarction. (2010) (144)
Iron deficiency and health-related quality of life in chronic heart failure: results from a multicenter European study. (2014) (144)
111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: a clue to uncover the mechanisms of trastuzumab-related cardiotoxicity. (2007) (144)
Prognostic value of heart rate variability in chronic congestive heart failure secondary to idiopathic or ischemic dilated cardiomyopathy. (1997) (144)
Epicardial fat in heart failure patients with mid‐range and preserved ejection fraction (2018) (143)
Angiotensin II-Receptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer: A Randomized Clinical Trial. (2016) (143)
Effect of metformin on left ventricular function after acute myocardial infarction in patients without diabetes: the GIPS-III randomized clinical trial. (2014) (142)
Plasma semicarbazide-sensitive amine oxidase is elevated in patients with congestive heart failure. (1997) (140)
Erythropoietin treatment in patients with chronic heart failure: a meta-analysis (2009) (140)
Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction (2019) (138)
Elevated plasma galectin-3 is associated with near-term rehospitalization in heart failure: a pooled analysis of 3 clinical trials. (2014) (137)
Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: Association With Exercise Capacity, Left Ventricular Filling Pressures, Natriuretic Peptides, and Left Atrial Volume. (2017) (137)
High- versus low-dose ACE inhibition in chronic heart failure: a double-blind, placebo-controlled study of imidapril. (1998) (135)
Volume status and diuretic therapy in systolic heart failure and the detection of early abnormalities in renal and tubular function. (2011) (132)
Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition. (2006) (129)
The effect of rate control on quality of life in patients with permanent atrial fibrillation: data from the RACE II (Rate Control Efficacy in Permanent Atrial Fibrillation II) study. (2011) (128)
Beta-blockers and outcome in heart failure and atrial fibrillation: a meta-analysis. (2013) (127)
Risk of complications during pregnancy after Senning or Mustard (atrial) repair of complete transposition of the great arteries. (2005) (127)
Effect of fluvastatin on ischaemia following acute myocardial infarction: a randomized trial. (2002) (124)
Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia. (2008) (123)
N-terminal pro-B-type natriuretic peptide is an independent predictor of cardiovascular morbidity and mortality in the general population. (2010) (122)
Comparison of plasma neurohormones in congestive heart failure patients with atrial fibrillation versus patients with sinus rhythm. (1998) (121)
Identification of genomic loci associated with resting heart rate and shared genetic predictors with all-cause mortality (2016) (121)
Effects of lisinopril in patients with heart failure and chronic atrial fibrillation. (1995) (120)
Development and testing of the Dutch Heart Failure Knowledge Scale. (2003) (120)
Lack of Prognostic Value of Type D Personality for Mortality in a Large Sample of Heart Failure Patients (2011) (117)
Outcome of pregnancy in patients after repair of aortic coarctation. (2005) (115)
Definition of Iron Deficiency Based on the Gold Standard of Bone Marrow Iron Staining in Heart Failure Patients (2018) (114)
Marital status, quality of life, and clinical outcome in patients with heart failure. (2006) (114)
Early detection of anthracycline induced cardiotoxicity in asymptomatic patients with normal left ventricular systolic function: autonomic versus echocardiographic variables (1999) (114)
Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial (2018) (110)
EURObservational Research Programme: a worldwide registry on peripartum cardiomyopathy (PPCM) in conjunction with the Heart Failure Association of the European Society of Cardiology Working Group on PPCM (2014) (110)
Relationship between left ventricular dysfunction and depression following myocardial infarction: data from the MIND-IT. (2005) (109)
Effect of rate and rhythm control on left ventricular function and cardiac dimensions in patients with persistent atrial fibrillation: results from the RAte Control versus Electrical Cardioversion for Persistent Atrial Fibrillation (RACE) study. (2005) (109)
Effect of rosuvastatin on repeat heart failure hospitalizations: the CORONA Trial (Controlled Rosuvastatin Multinational Trial in Heart Failure). (2014) (107)
Diabetes, Glycemic Control, and New-Onset Heart Failure in Patients With Stable Coronary Artery Disease (2010) (106)
Obstetric complications in Marfan syndrome. (2006) (105)
Non-cardiac comorbidities in heart failure with reduced, mid-range and preserved ejection fraction. (2018) (105)
Pregnancy, fertility, and recurrence risk in corrected tetralogy of Fallot (2005) (104)
Long-term chemotherapy-related cardiovascular morbidity. (2000) (104)
Separating the Mechanism-Based and Off-Target Actions of Cholesteryl Ester Transfer Protein Inhibitors With CETP Gene Polymorphisms (2010) (104)
Short-term vitamin D3 supplementation lowers plasma renin activity in patients with stable chronic heart failure: an open-label, blinded end point, randomized prospective trial (VitD-CHF trial). (2013) (102)
Electrical and structural remodeling: role in the genesis and maintenance of atrial fibrillation. (2005) (101)
52 Genetic Loci Influencing Myocardial Mass. (2016) (98)
Prognostic Value of Plasma Neutrophil Gelatinase–Associated Lipocalin for Mortality in Patients With Heart Failure (2014) (98)
The Chronic Kidney Disease Epidemiology Collaboration equation outperforms the Modification of Diet in Renal Disease equation for estimating glomerular filtration rate in chronic systolic heart failure (2014) (97)
Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: insights from the SENIORS trial (2009) (96)
Lenient vs. strict rate control in patients with atrial fibrillation and heart failure: a post‐hoc analysis of the RACE II study (2013) (96)
For Better and For Worse: Quality of Life Impaired in HF Patients as well as in Their Partners (2005) (95)
Effect of age and sex on efficacy and tolerability of β blockers in patients with heart failure with reduced ejection fraction: individual patient data meta-analysis (2016) (95)
Tubular damage and worsening renal function in chronic heart failure. (2013) (94)
The use of digoxin in patients with worsening chronic heart failure: reconsidering an old drug to reduce hospital admissions. (2014) (92)
Qualitative examination of compliance in heart failure patients in The Netherlands. (2010) (92)
Cancer and heart disease: associations and relations (2019) (91)
α‐Actin isoform distribution in normal and failing human heart: a morphological, morphometric, and biochemical study (2003) (91)
Myocardial infarction enhances progressive renal damage in an experimental model for cardio-renal interaction. (2004) (91)
One-Year Outcomes After Transcatheter Insertion of an Interatrial Shunt Device for the Management of Heart Failure With Preserved Ejection Fraction (2016) (90)
C-reactive protein and microalbuminuria are associated with atrial fibrillation. (2005) (90)
The influence of renal function on clinical outcome and response to beta-blockade in systolic heart failure: insights from Metoprolol CR/XL Randomized Intervention Trial in Chronic HF (MERIT-HF). (2009) (89)
Severe myocardial fibrosis caused by a deletion of the 5' end of the lamin A/C gene. (2007) (89)
Right ventricular-vascular coupling in heart failure with preserved ejection fraction and pre- vs. post-capillary pulmonary hypertension (2018) (88)
Clinical and prognostic value of advanced glycation end-products in chronic heart failure. (2007) (88)
Uteroplacental Blood Flow, Cardiac Function, and Pregnancy Outcome in Women With Congenital Heart Disease (2013) (87)
Biomarkers of renal injury and function: diagnostic, prognostic and therapeutic implications in heart failure. (2016) (87)
Hemoglobin levels and 30-day mortality in patients after myocardial infarction. (2005) (87)
Development and Testing of the Dutch Heart Failure Knowledge Scale (2005) (86)
Tolerability and dose-related effects of nebivolol in elderly patients with heart failure: data from the Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with Heart Failure (SENIORS) trial. (2007) (85)
Non-cardiac complications during pregnancy in women with isolated congenital pulmonary valvar stenosis (2006) (83)
Role of Troponins I and T and N-Terminal Prohormone of Brain Natriuretic Peptide in Monitoring Cardiac Safety of Patients With Early-Stage Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Trastuzumab: A Herceptin Adjuvant Study Cardiac Marker Substudy. (2017) (83)
N-terminal pro-B-type natriuretic peptide predicts cardiovascular complications in pregnant women with congenital heart disease. (2014) (83)
Biomarker Profiles of Acute Heart Failure Patients With a Mid-Range Ejection Fraction. (2017) (82)
Neutrophil Gelatinase-Associated Lipocalin for Acute Kidney Injury During Acute Heart Failure Hospitalizations: The AKINESIS Study. (2016) (82)
Optimizing clinical use of biomarkers in high‐risk acute heart failure patients (2016) (82)
Incremental prognostic power of novel biomarkers (growth-differentiation factor-15, high-sensitivity C-reactive protein, galectin-3, and high-sensitivity troponin-T) in patients with advanced chronic heart failure. (2013) (81)
Physical Activity Measured With Implanted Devices Predicts Patient Outcome in Chronic Heart Failure (2014) (81)
Pregnancy in women with corrected tetralogy of Fallot: occurrence and predictors of adverse events. (2011) (81)
Extracellular matrix turnover and inflammatory markers independently predict functional status and outcome in chronic heart failure. (2008) (81)
Effect of eplerenone in patients with heart failure and reduced ejection fraction: potential effect modification by abdominal obesity. Insight from the EMPHASIS‐HF trial (2017) (80)
Adequacy of endogenous erythropoietin levels and mortality in anaemic heart failure patients. (2008) (80)
Heart rate variability in left ventricular dysfunction and heart failure: effects and implications of drug treatment. (1994) (79)
Waist‐to‐hip ratio and mortality in heart failure (2018) (79)
Telomere biology in cardiovascular disease: the TERC-/- mouse as a model for heart failure and ageing. (2008) (78)
Continuous vs episodic prophylactic treatment with amiodarone for the prevention of atrial fibrillation: a randomized trial. (2008) (78)
Prognostic value of mid-regional pro-adrenomedullin in patients with heart failure after an acute myocardial infarction (2011) (78)
Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction: findings from BIOSTAT‐CHF (2017) (77)
Management of atrial fibrillation in the setting of heart failure. (1997) (77)
Plasma semicarbazide-sensitive amine oxidase (SSAO) is an independent prognostic marker for mortality in chronic heart failure. (2000) (77)
Hypochloremia, Diuretic Resistance, and Outcome in Patients With Acute Heart Failure (2016) (77)
Comparison of the temporal release pattern of copeptin with conventional biomarkers in acute myocardial infarction (2011) (77)
Rate control is more cost-effective than rhythm control for patients with persistent atrial fibrillation--results from the RAte Control versus Electrical cardioversion (RACE) study. (2004) (76)
Cardiac complications relating to pregnancy and recurrence of disease in the offspring of women with atrioventricular septal defects. (2005) (76)
The impact of eplerenone at different levels of risk in patients with systolic heart failure and mild symptoms: insight from a novel risk score for prognosis derived from the EMPHASIS-HF trial. (2013) (75)
Beyond the cardiorenal anaemia syndrome: recognizing the role of iron deficiency (2012) (74)
Role of inflammation in early atrial fibrillation recurrence. (2012) (74)
The cardiopulmonary continuum systemic inflammation as 'common soil' of heart and lung disease. (2010) (74)
Vascular endothelial growth factor is crucial for erythropoietin-induced improvement of cardiac function in heart failure. (2010) (73)
Echocardiographic estimation of left ventricular and pulmonary pressures in patients with heart failure and preserved ejection fraction: a study utilizing simultaneous echocardiography and invasive measurements (2017) (73)
RAte Control Efficacy in permanent atrial fibrillation: a comparison between lenient versus strict rate control in patients with and without heart failure. Background, aims, and design of RACE II. (2006) (73)
Low pulse pressure is independently related to elevated natriuretic peptides and increased mortality in advanced chronic heart failure. (2005) (73)
Latest insights in therapeutic options for systemic right ventricular failure: a comparison with left ventricular failure (2008) (72)
Neurohormonal and clinical sex differences in heart failure. (2013) (71)
Gender-specific changes in quality of life following cardiovascular disease: a prospective study. (2002) (71)
Tezosentan in patients with acute heart failure: design of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Study (VERITAS). (2005) (70)
Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial. (2019) (70)
Combined utility of brain natriuretic peptide and cardiac troponin T may improve rapid triage and risk stratification in normotensive patients with pulmonary embolism. (2007) (69)
Digoxin in patients with permanent atrial fibrillation: data from the RACE II study. (2014) (69)
Erythropoiesis-stimulating agents for anaemia in chronic heart failure patients. (2010) (69)
Efficacy of folic acid when added to statin therapy in patients with hypercholesterolemia following acute myocardial infarction: a randomised pilot trial. (2004) (69)
Self-reported versus ‘true’ adherence in heart failure patients: a study using the Medication Event Monitoring System (2012) (69)
Clinical Risk Stratification Optimizes Value of Biomarkers to Predict New-Onset Heart Failure in a Community-Based Cohort (2014) (68)
Biomarkers and low risk in heart failure. Data from COACH and TRIUMPH (2015) (68)
Impaired renal function in patients with ischemic and nonischemic chronic heart failure: association with neurohormonal activation and survival. (2004) (68)
Aging, telomeres and heart failure (2010) (68)
Differences in drug treatment of chronic heart failure between European countries. (1999) (68)
Statins in the treatment of chronic heart failure: biological and clinical considerations. (2006) (67)
Additional use of immunostaining for active caspase 3 and cleaved actin and PARP fragments to detect apoptosis in patients with chronic heart failure. (2000) (67)
A Systematic Review and Network-Meta-Analysis of Pharmacological Treatment of Heart Failure With Reduced Ejection Fraction (2021) (66)
Comparison of gated PET with MRI for evaluation of left ventricular function in patients with coronary artery disease. (2004) (66)
Long‐term follow‐up in optimally treated and stable heart failure patients: primary care vs. heart failure clinic. Results of the COACH‐2 study (2014) (65)
Association with outcomes and response to treatment of trimethylamine N‐oxide in heart failure: results from BIOSTAT‐CHF (2018) (65)
Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with Heart Failure (SENIORS). Rationale and design. (2002) (65)
Blood urea nitrogen-to-creatinine ratio in the general population and in patients with acute heart failure (2016) (65)
High prevalence of microalbuminuria in chronic heart failure patients. (2005) (64)
Digoxin reduces 30-day all-cause hospital admission in older patients with chronic systolic heart failure. (2013) (64)
Fibrosis Marker Syndecan-1 and Outcome in Patients With Heart Failure With Reduced and Preserved Ejection Fraction (2014) (64)
Depression and the usefulness of a disease management program in heart failure: insights from the COACH (Coordinating study evaluating Outcomes of Advising and Counseling in Heart failure) study. (2010) (63)
The association between neutrophil gelatinase‐associated lipocalin and clinical outcome in chronic heart failure: results from CORONA * (2011) (63)
The additive burden of iron deficiency in the cardiorenal–anaemia axis: scope of a problem and its consequences (2014) (63)
Endogenous Erythropoietin and Outcome in Heart Failure (2010) (62)
Selenium and outcome in heart failure (2019) (62)
Metformin in non-Diabetic Patients Presenting with ST Elevation Myocardial Infarction: Rationale and Design of the Glycometabolic Intervention as Adjunct to Primary Percutaneous Intervention in ST Elevation Myocardial Infarction (GIPS)-III Trial (2012) (62)
New roles for renin and prorenin in heart failure and cardiorenal crosstalk (2011) (62)
Acute heart failure in the elderly: differences in clinical characteristics, outcomes, and prognostic factors in the VERITAS Study. (2015) (62)
A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial (2019) (62)
Effects of erythropoietin after an acute myocardial infarction: rationale and study design of a prospective, randomized, clinical trial (HEBE III). (2008) (61)
Rate control in atrial fibrillation. (2004) (60)
Digoxin use and lower 30-day all-cause readmission for Medicare beneficiaries hospitalized for heart failure. (2014) (60)
Secondary prevention with folic acid: results of the Goes extension study (2005) (60)
Low circulating microRNA levels in heart failure patients are associated with atherosclerotic disease and cardiovascular-related rehospitalizations (2017) (60)
Determinants and outcome of amiodarone‐associated thyroid dysfunction (2011) (60)
Heart failure with normal left ventricular ejection fraction: what is the evidence? (2008) (59)
The VEGF +405 CC promoter polymorphism is associated with an impaired prognosis in patients with chronic heart failure: a MERIT-HF substudy. (2005) (59)
Unraveling the mechanisms for heart failure patients' beliefs about compliance. (2007) (59)
The role of advanced glycation end-products and their receptor on outcome in heart failure patients with preserved and reduced ejection fraction. (2012) (59)
Statins in the Treatment of Chronic Heart Failure: A Systematic Review (2006) (58)
Mild preoperative renal dysfunction as a predictor of long-term clinical outcome after coronary bypass surgery. (2005) (58)
Telomere length and outcome in heart failure. (2010) (58)
Potassium and the use of renin–angiotensin–aldosterone system inhibitors in heart failure with reduced ejection fraction: data from BIOSTAT‐CHF (2018) (58)
Telomere length and psychological well-being in patients with chronic heart failure. (2010) (57)
Right ventricular pacing and the risk of heart failure in implantable cardioverter-defibrillator patients. (2006) (57)
Clinical presentation, management, and 6-month outcomes in women with peripartum cardiomyopathy: an ESC EORP registry. (2020) (57)
Prediction of depressive disorder following myocardial infarction data from the Myocardial INfarction and Depression-Intervention Trial (MIND-IT). (2005) (56)
Atrial natriuretic peptide in patients with heart failure and chronic atrial fibrillation: role of duration of atrial fibrillation. (1998) (56)
Prediction of functional recovery after revascularization in patients with coronary artery disease and left ventricular dysfunction by gated FDG-PET. (2006) (56)
Iron deficiency in worsening heart failure is associated with reduced estimated protein intake, fluid retention, inflammation, and antiplatelet use (2019) (56)
Efficacy and safety of calcium channel blockers in heart failure: focus on recent trials with second-generation dihydropyridines. (2000) (56)
Effect of spironolactone on 30-day death and heart failure rehospitalization (from the COACH Study). (2014) (55)
Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure: Rationale and Design of the Randomized Trial to REDUCE Elevated Left Atrial Pressure in Heart Failure (REDUCE LAP-HF I) (2016) (55)
Ketone Ester Treatment Improves Cardiac Function and Reduces Pathologic Remodeling in Preclinical Models of Heart Failure (2020) (55)
Mending the rhythm does not improve prognosis in patients with persistent atrial fibrillation: a subanalysis of the RACE study. (2006) (55)
Bio‐adrenomedullin as a marker of congestion in patients with new‐onset and worsening heart failure (2019) (54)
Myocardial β-adrenoceptor downregulation in idiopathic dilated cardiomyopathy measured in vivo with PET using the new radioligand (S)-[11C]CGP12388 (2005) (54)
Usefulness of elevated neopterin and C-reactive protein levels in predicting cardiovascular events in patients with non-Q-wave myocardial infarction. (2003) (54)
Effects of sildenafil on cardiac structure and function, cardiopulmonary exercise testing and health‐related quality of life measures in heart failure patients with preserved ejection fraction and pulmonary hypertension (2017) (54)
A network analysis to compare biomarker profiles in patients with and without diabetes mellitus in acute heart failure (2017) (54)
Use of cystatin C levels in estimating renal function and prognosis in patients with chronic systolic heart failure (2011) (53)
Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) (2020) (53)
Impact of mineralocorticoid receptor antagonists on the risk of sudden cardiac death in patients with heart failure and left-ventricular systolic dysfunction: an individual patient-level meta-analysis of three randomized-controlled trials (2018) (52)
Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm: A Post Hoc Analysis of the COMMANDER HF Trial. (2019) (52)
Differential effects of high-frequency versus low-frequency exercise training in rehabilitation of patients with coronary artery disease. (2000) (52)
Prognostic importance of renal function in patients with early heart failure and mild left ventricular dysfunction. (2004) (52)
Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure (2020) (52)
ECG determinants in adult patients with chronic right ventricular pressure overload caused by congenital heart disease: relation with plasma neurohormones and MRI parameters (2002) (52)
Long-term compliance with nonpharmacologic treatment of patients with heart failure. (2012) (51)
Efficacy and safety of direct oral anticoagulants during pregnancy; a systematic literature review. (2018) (51)
Current and novel renal biomarkers in heart failure (2011) (51)
Angiotensin-Neprilysin Inhibition and Renal Outcomes in Heart Failure With Preserved Ejection Fraction (2020) (51)
Influence of age on neurohormonal activation and prognosis in patients with chronic heart failure. (1998) (51)
Perceived sexual difficulties and associated factors in patients with heart failure. (2012) (51)
Relation between severity of disease and impairment of heart rate variability parameters in patients with chronic congestive heart failure secondary to coronary artery disease. (1995) (51)
Plasma interleukin 6 levels are associated with cardiac function after ST-elevation myocardial infarction (2018) (50)
Persistent atrial fibrillation is associated with appropriate shocks and heart failure in patients with left ventricular dysfunction treated with an implantable cardioverter defibrillator. (2007) (50)
Mild renal dysfunction is associated with electrocardiographic left ventricular hypertrophy. (2005) (50)
Skin-autofluorescence, a measure of tissue advanced glycation end-products (AGEs), is related to diastolic function in dialysis patients. (2008) (50)
Use of biomarkers to establish potential role and function of circulating microRNAs in acute heart failure. (2016) (50)
Increased expression of cardiac angiotensin II type 1 (AT(1)) receptors decreases myocardial microvessel density after experimental myocardial infarction. (2003) (49)
Effect of lenient versus strict rate control on cardiac remodeling in patients with atrial fibrillation data of the RACE II (RAte Control Efficacy in permanent atrial fibrillation II) study. (2011) (49)
Atrial Ultrastructural Changes During Experimental Atrial Tachycardia Depend on High Ventricular Rate (2004) (49)
The Objective Burden in Partners of Heart Failure Patients; Development and Initial Validation of the Dutch Objective Burden Inventory (2008) (49)
Fibroblast growth factor 23 is related to profiles indicating volume overload, poor therapy optimization and prognosis in patients with new-onset and worsening heart failure. (2018) (49)
Right Heart Dysfunction in Heart Failure With Preserved Ejection Fraction: The Impact of Atrial Fibrillation. (2017) (49)
PET for evaluation of differential myocardial perfusion dynamics after VEGF gene therapy and laser therapy in end-stage coronary artery disease. (2004) (48)
Quantitative assessment of the pressure and volume overloaded right ventricle: imaging is a real challenge (2002) (48)
Possible association between telomere length and renal dysfunction in patients with chronic heart failure. (2008) (48)
Rate control efficacy in permanent atrial fibrillation: successful and failed strict rate control against a background of lenient rate control: data from RACE II (Rate Control Efficacy in Permanent Atrial Fibrillation). (2013) (48)
A trial-based economic evaluation of 2 nurse-led disease management programs in heart failure. (2011) (48)
Genetic Determinants of P Wave Duration and PR Segment (2014) (48)
Sex‐specific associations of obesity and N‐terminal pro‐B‐type natriuretic peptide levels in the general population (2018) (47)
Prognostic value of N‐terminal pro C‐type natriuretic peptide in heart failure patients with preserved and reduced ejection fraction (2014) (47)
Telomere Length of Circulating Leukocyte Subpopulations and Buccal Cells in Patients with Ischemic Heart Failure and Their Offspring (2011) (47)
Comparing biomarker profiles of patients with heart failure: atrial fibrillation vs. sinus rhythm and reduced vs. preserved ejection fraction (2018) (46)
Advanced Glycation Endproducts in Chronic Heart Failure (2008) (46)
Educational level and the quality of life of heart failure patients: a longitudinal study. (2011) (46)
Value of digoxin in heart failure and sinus rhythm: new features of an old drug? (1996) (46)
The WAP four-disulfide core domain protein HE4: a novel biomarker for heart failure. (2013) (46)
Advanced glycation end-products, a pathophysiological pathway in the cardiorenal syndrome (2011) (45)
Myocardial fibrosis as an early feature in phospholamban p.Arg14del mutation carriers: phenotypic insights from cardiovascular magnetic resonance imaging (2019) (45)
Cardiac resynchronization therapy in patients with heart failure and atrial fibrillation: importance of new-onset atrial fibrillation and total atrial conduction time. (2008) (45)
Machine learning based on biomarker profiles identifies distinct subgroups of heart failure with preserved ejection fraction (2021) (44)
Dose response characterization of the association of serum digoxin concentration with mortality outcomes in the Digitalis Investigation Group trial (2016) (44)
Vascular endothelial growth factor: the link between cardiovascular risk factors and microalbuminuria? (2004) (44)
Effect of EPO administration on myocardial infarct size in patients with non-STE acute coronary syndromes; results from a pilot study. (2009) (44)
Effect of intensive versus moderate lipid lowering on endothelial function and vascular responsiveness to angiotensin II in stable coronary artery disease. (2005) (44)
Serial galectin-3 and future cardiovascular disease in the general population (2016) (44)
The underreporting of results and possible mechanisms of 'negative' drug trials in patients with chronic heart failure. (2001) (44)
Fatigue as a predictor of outcome in patients with heart failure: analysis of CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure). (2014) (43)
A comparison of low versus high heart rate in patients with atrial fibrillation and advanced chronic heart failure: effects on clinical profile, neurohormones and survival. (2006) (43)
Value of ambulatory electrocardiographic monitoring to identify increased risk of sudden death in patients with left ventricular dysfunction and heart failure. (1994) (43)
Physiological parameters during the initial stages of cardiopulmonary exercise testing in patients with chronic heart failure. Their value in the assessment of clinical severity and prognosis. (1997) (43)
Natriuretic peptides in patients with atrial fibrillation and advanced chronic heart failure: determinants and prognostic value of (NT-)ANP and (NT-pro)BNP. (2007) (43)
Renal function stratified dose comparisons of eplerenone versus placebo in the EMPHASIS‐HF trial (2019) (42)
Prognosis of atrial fibrillation in congestive heart failure. (2004) (42)
Fractin immunostaining for the detection of apoptotic cells and apoptotic bodies in formalin-fixed and paraffin-embedded tissue. (1999) (42)
Circulating Leukocyte and Carotid Atherosclerotic Plaque Telomere Length: Interrelation, Association With Plaque Characteristics, and Restenosis After Endarterectomy (2011) (42)
Depressive symptoms and inflammation in patients hospitalized for heart failure. (2011) (42)
The cardiorenal syndrome in heart failure. (2011) (42)
A Genome-Wide Association Study of Circulating Galectin-3 (2012) (42)
The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT (2013) (41)
Serum Potassium Levels and Outcome in Acute Heart Failure (Data from the PROTECT and COACH Trials). (2017) (41)
The emerging role of telomere biology in cardiovascular disease. (2010) (41)
Impact of atrial fibrillation on mortality in patients with chronic heart failure. (2002) (41)
Urinary N-Terminal Prohormone Brain Natriuretic Peptide Excretion in Patients With Chronic Heart Failure (2009) (41)
Concentric vs. eccentric remodelling in heart failure with reduced ejection fraction: clinical characteristics, pathophysiology and response to treatment (2019) (41)
Cardioversion of atrial fibrillation in the setting of mild to moderate heart failure. (1998) (40)
Associations between cardiovascular parameters and uteroplacental Doppler (blood) flow patterns during pregnancy in women with congenital heart disease: Rationale and design of the Zwangerschap bij Aangeboren Hartafwijking (ZAHARA) II study. (2011) (40)
Prognostic importance of emerging cardiac, inflammatory, and renal biomarkers in chronic heart failure patients with reduced ejection fraction and anaemia: RED‐HF study (2017) (40)
Beta-blockers prevent subacute recurrences of persistent atrial fibrillation only in patients with hypertension. (2004) (40)
Clinical importance of urinary sodium excretion in acute heart failure (2020) (40)
Long-term anti-ischemic effects of angiotensin-converting enzyme inhibition in patients after myocardial infarction. The Captopril and Thrombolysis Study (CATS) Investigators. (1997) (40)
Biomarker-Guided Versus Guideline-Based Treatment of Patients With Heart Failure: Results From BIOSTAT-CHF. (2018) (39)
Favorable long-term outcome of Maze surgery in patients with lone atrial fibrillation. (2006) (39)
Resource utilization and costs in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. (2005) (39)
Erythropoietin in the General Population: Reference Ranges and Clinical, Biochemical and Genetic Correlates (2015) (39)
Pretreatment with ACE inhibitors improves acute outcome of electrical cardioversion in patients with persistent atrial fibrillation (2005) (38)
MicroRNAs relate to early worsening of renal function in patients with acute heart failure. (2016) (38)
A combined clinical and biomarker approach to predict diuretic response in acute heart failure (2015) (38)
Long-term effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria:Ten years of follow-up of Prevention of Renal and Vascular End-stage Disease Intervention Trial (PREVEND IT). (2011) (38)
Impact of interventricular lead distance and the decrease in septal-to-lateral delay on response to cardiac resynchronization therapy. (2008) (38)
Atrial fibrillation predicts appropriate shocks in primary prevention implantable cardioverter-defibrillator patients. (2006) (38)
Clinical correlates and prognostic impact of impaired iron storage versus impaired iron transport in an international cohort of 1821 patients with chronic heart failure. (2017) (38)
Routine versus aggressive upstream rhythm control for prevention of early atrial fibrillation in heart failure: background, aims and design of the RACE 3 study (2013) (37)
Right ventricular recovery after bilateral lung transplantation for pulmonary arterial hypertension†. (2017) (37)
Management of heart failure in The Netherlands (2005) (37)
Clustering of RR Intervals Predicts Effective Electrical Cardioversion for Atrial Fibrillation (2004) (37)
Sexual problems in elderly male and female patients with heart failure (2012) (37)
Genome-Wide Association Study on Plasma Levels of Midregional-Proadrenomedullin and C-Terminal-Pro-Endothelin-1 (2013) (37)
Prediction of 6 months left ventricular dilatation after myocardial infarction in relation to cardiac morbidity and mortality. Application of a new dilatation model to GISSI-3 data. (2002) (37)
Impact of eplerenone on cardiovascular outcomes in heart failure patients with hypokalaemia (2017) (36)
Combining Diuretic Response and Hemoconcentration to Predict Rehospitalization After Admission for Acute Heart Failure (2016) (36)
Early expression of natriuretic peptides and SERCA in mild heart failure: association with severity of the disease. (2001) (36)
Central and Peripheral Determinants of Exercise Capacity in Heart Failure Patients With Preserved Ejection Fraction. (2019) (36)
The PCSK9-LDL Receptor Axis and Outcomes in Heart Failure: BIOSTAT-CHF Subanalysis. (2017) (36)
Enhanced cardiovascular morbidity and mortality during rhythm control treatment in persistent atrial fibrillation in hypertensives: data of the RACE study. (2007) (36)
A re-appraisal of volume status and renal function impairment in chronic heart failure: combined effects of pre-renal failure and venous congestion on renal function (2011) (36)
Myocardial Perfusion Reserve After a PET-Driven Revascularization Procedure: A Strong Prognostic Factor (2011) (36)
Factors associated with patient delay in seeking care after worsening symptoms in heart failure patients. (2011) (36)
Addition of an angiotensin receptor blocker to full-dose ACE-inhibition: controversial or common sense? (2005) (36)
Rapid bedside measurement of brain natriuretic peptide in patients with chronic heart failure. (2002) (36)
Patients with heart failure with preserved ejection fraction and low levels of natriuretic peptides (2016) (36)
Verapamil versus digoxin and acute versus routine serial cardioversion for the improvement of rhythm control for persistent atrial fibrillation. (2006) (35)
Dynamics of cerebral blood flow in patients with mild non‐ischaemic heart failure (2017) (35)
Accumulation of 5-oxoproline in myocardial dysfunction and the protective effects of OPLAH (2017) (35)
Maternal cardiac function, uteroplacental Doppler flow parameters and pregnancy outcome: a systematic review (2015) (35)
Novel endotypes in heart failure: effects on guideline-directed medical therapy (2018) (35)
Clinical Benefit of Eplerenone in Patients With Mild Symptoms of Systolic Heart Failure Already Receiving Optimal Best Practice Background Drug Therapy: Analysis of the EMPHASIS-HF Study (2013) (35)
Heart failure in the outpatient versus inpatient setting: findings from the BIOSTAT‐CHF study (2018) (35)
Serum ferritin and risk for new‐onset heart failure and cardiovascular events in the community (2017) (35)
Rationale for and design of the TRUE‐AHF trial: the effects of ularitide on the short‐term clinical course and long‐term mortality of patients with acute heart failure (2017) (35)
Iron deficiency and red cell indices in patients with heart failure (2018) (35)
Increased risk of stroke with darbepoetin alfa in anaemic heart failure patients with diabetes and chronic kidney disease (2015) (35)
Galectin-3 and sST2 in prediction of left ventricular ejection fraction after myocardial infarction. (2016) (35)
Management of atrial fibrillation in patients with heart failure. (2007) (34)
Importance of Heart Rate During Exercise for Response to Cardiac Resynchronization Therapy (2009) (34)
Lack of specific renal haemodynamic effects of different doses of dopamine after infrarenal aortic surgery. (1996) (34)
Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF) (2013) (33)
Procalcitonin-based indication of bacterial infection identifies high risk acute heart failure patients. (2016) (33)
Chronic beta-blocker treatment in patients with advanced heart failure. Effects on neurohormones. (2000) (33)
Plasma renin and outcome in the community: data from PREVEND. (2012) (33)
Heart failure with preserved ejection fraction, atrial fibrillation, and the role of senile amyloidosis (2019) (33)
Four Genetic Loci Influencing Electrocardiographic Indices of Left Ventricular Hypertrophy (2011) (32)
Worsening heart failure, a critical event during hospital admission for acute heart failure: results from the VERITAS study (2014) (32)
Low pulse pressure is an independent predictor of mortality and morbidity in non ischaemic, but not in ischaemic advanced heart failure patients. (2009) (32)
Evaluation of long term cardiotoxicity after epirubicin containing adjuvant chemotherapy and locoregional radiotherapy for breast cancer using various detection techniques (2002) (32)
Predictors of mortality in patients with sustained ventricular tachycardias or ventricular fibrillation and depressed left ventricular function: importance of beta-blockade. (1995) (32)
Individual assessment of intensity-level for exercise training in patients with coronary artery disease is necessary. (2002) (32)
Cardiotoxicity associated with the use of trastuzumab in breast cancer patients (2007) (32)
β-blockade with nebivolol for prevention of acute ischaemic events in elderly patients with heart failure (2010) (32)
Pulmonary valve replacement: twenty-six years of experience with mechanical valvar prostheses. (2015) (32)
Anemia in chronic heart failure: etiology and treatment options (2008) (31)
Anemia in Heart Failure: Still Relevant? (2018) (31)
Predictors and Associations With Outcomes of Length of Hospital Stay in Patients With Acute Heart Failure: Results From VERITAS. (2016) (31)
The year in cardiology 2018: heart failure (2019) (31)
Prognostic importance of natriuretic peptides and atrial fibrillation in patients receiving cardiac resynchronization therapy (2011) (31)
Renal dysfunction is associated with shorter telomere length in heart failure (2009) (31)
Impact of Renal Impairment on Beta-Blocker Efficacy in Patients With Heart Failure. (2019) (31)
Relation between genotype and left-ventricular dilatation in patients with Marfan syndrome. (2009) (31)
Does intensity of rate control influence outcome in persistent atrial fibrillation? Data of the RACE study. (2009) (31)
Endothelium dependent relaxation in two different models of chronic heart failure and the effect of ibopamine. (1993) (31)
Impact of atrial fibrillation on rest and exercise haemodynamics in heart failure with mid‐range and preserved ejection fraction (2017) (31)
Right Ventricular Function After Acute Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention (from the Glycometabolic Intervention as Adjunct to Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction III Trial). (2016) (30)
Clinical benefits of eplerenone in patients with systolic heart failure and mild symptoms when initiated shortly after hospital discharge: analysis from the EMPHASIS-HF trial. (2015) (30)
Ischemia and left ventricular dysfunction: a reciprocal relation? (1998) (30)
Thyroid-stimulating hormone and clinical outcomes: the CORONA trial (controlled rosuvastatin multinational study in heart failure). (2014) (30)
Comparison of effects on peak oxygen consumption, quality of life, and neurohormones of felodipine and enalapril in patients with congestive heart failure. (1995) (29)
A family with Andersen-Tawil syndrome and dilated cardiomyopathy. (2006) (29)
Nebivolol: third-generation β-blockade (2007) (29)
Plasma kidney injury molecule‐1 in heart failure: renal mechanisms and clinical outcome (2016) (29)
Acute anti-ischemic effects of perindoprilat in men with coronary artery disease and their relation with left ventricular function. (1999) (29)
Hyperkalemia and Treatment With RAAS-Inhibitors During Acute Heart Failure Hospitalizations and Their Association With Mortality. (2019) (28)
Heart failure-associated anemia: bone marrow dysfunction and response to erythropoietin (2010) (28)
Measurement of troponin and natriuretic peptides shortly after admission in patients with heart failure—does it add useful prognostic information? An analysis of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Studies (VERITAS) (2017) (28)
The influence of atrial fibrillation on the levels of NT-proBNP versus GDF-15 in patients with heart failure (2019) (28)
Effect of very early angiotensin-converting enzyme inhibition on left ventricular dilation after myocardial infarction in patients receiving thrombolysis: results of a meta-analysis of 845 patients. FAMIS, CAPTIN and CATS Investigators. (2000) (28)
Epicardial Adipose Tissue and Invasive Hemodynamics in Heart Failure With Preserved Ejection Fraction. (2020) (28)
Cardiac adaption during pregnancy in women with congenital heart disease and healthy women (2016) (28)
Cost-effectiveness of eplerenone in patients with systolic heart failure and mild symptoms (2014) (27)
Chronotropic response to exercise in patients with atrial fibrillation: relation to functional state. (1993) (27)
Differences in Clinical Profile and Outcomes of Low Iron Storage vs Defective Iron Utilization in Patients With Heart Failure: Results From the DEFINE-HF and BIOSTAT-CHF Studies. (2019) (27)
Symptom severity is associated with cardiovascular outcome in patients with permanent atrial fibrillation in the RACE II study. (2014) (27)
Pulmonary regurgitant volume is superior to fraction using background-corrected phase contrast MRI in determining the severity of regurgitation in repaired tetralogy of Fallot (2015) (27)
Utility of a BNP as a marker for RV dysfunction in acute pulmonary embolism. (2002) (27)
Genome-Wide Meta-Analyses of Plasma Renin Activity and Concentration Reveal Association With the Kininogen 1 and Prekallikrein Genes (2015) (26)
Cardiac function and cardiac events 1-year postpartum in women with congenital heart disease. (2015) (26)
Clinical characteristics of persistent lone atrial fibrillation in the RACE study. (2004) (26)
Clinical and Hemodynamic Correlates and Prognostic Value of VE/VCO2 Slope in Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Hypertension. (2017) (26)
Health-related quality of life and anemia in hospitalized patients with heart failure. (2012) (26)
Clinical Correlates and Prognostic Value of Proenkephalin in Acute and Chronic Heart Failure. (2017) (25)
Digoxin for patients with atrial fibrillation and heart failure: paradise lost or not? (2013) (25)
OPLAH ablation leads to accumulation of 5-oxoproline, oxidative stress, fibrosis, and elevated fillings pressures: a murine model for heart failure with a preserved ejection fraction (2018) (25)
Effect of first myocardial ischemic event on renal function. (2007) (25)
Proteomic diversity of high‐density lipoprotein explains its association with clinical outcome in patients with heart failure (2018) (25)
Uteroplacental Doppler flow and pregnancy outcome in women with tetralogy of Fallot (2017) (25)
The effect of metformin on cardiovascular risk profile in patients without diabetes presenting with acute myocardial infarction: data from the Glycometabolic Intervention as adjunct to Primary Coronary Intervention in ST Elevation Myocardial Infarction (GIPS-III) trial (2015) (25)
Diastolic function measurements and diagnostic consequences: a comparison of pulsed wave- and color-coded tissue Doppler imaging (2009) (25)
Correlates of B-type natriuretic peptide and 6-min walk in heart failure patients. (2006) (25)
Heart Failure Clinics in the Netherlands in 2003 (2004) (24)
The importance of myocardial contractile reserve in predicting response to cardiac resynchronization therapy (2017) (24)
Plasma proteomic approach in patients with heart failure: insights into pathogenesis of disease progression and potential novel treatment targets (2019) (24)
Functional and hemodynamic cardiac determinants of exercise capacity in patients with systolic heart failure. (2012) (24)
Ventricular tachyarrhythmia detection by implantable loop recording in patients with heart failure and preserved ejection fraction: the VIP‐HF study (2020) (24)
Gender-specific risk factors for mortality associated with incident coronary heart disease--a prospective community-based study. (2006) (24)
Low prevalence of B-type natriuretic peptide levels < 100 pg/mL in patients with heart failure at hospital discharge. (2006) (24)
Paroxysmal atrial fibrillation, quality of life and neuroticism. (2005) (23)
A perspective on re‐evaluating digoxin's role in the current management of patients with chronic systolic heart failure: targeting serum concentration to reduce hospitalization and improve safety profile (2014) (23)
Vitamin B12 and folate deficiency in chronic heart failure (2014) (23)
The contemporary value of peak creatine kinase‐MB after ST‐segment elevation myocardial infarction above other clinical and angiographic characteristics in predicting infarct size, left ventricular ejection fraction, and mortality (2017) (23)
Genetic aspects of atrial fibrillation. (2005) (23)
Erythropoietin in cardiac disease: new features of an old drug. (2008) (23)
Depletion of atrial natriuretic peptide during longstanding atrial fibrillation. (2004) (23)
Telomere length and outcomes in ischaemic heart failure: data from the COntrolled ROsuvastatin multiNAtional Trial in Heart Failure (CORONA) (2015) (23)
Two-year follow-up of 4 months metformin treatment vs. placebo in ST-elevation myocardial infarction: data from the GIPS-III RCT (2017) (23)
Time-course of depressive symptoms in patients with heart failure. (2013) (23)
Plasma biomarkers to predict or rule out early post‐discharge events after hospitalization for acute heart failure (2017) (23)
Abnormalities in myocardial contractility, metabolism and perfusion reserve in non-stenotic coronary segments in heart failure patients. (2002) (22)
Twenty-eight genetic loci associated with ST-T-wave amplitudes of the electrocardiogram (2016) (22)
Renal Compression in Heart Failure: The Renal Tamponade Hypothesis. (2022) (22)
Data-Driven Approach to Identify Subgroups of Heart Failure With Reduced Ejection Fraction Patients With Different Prognoses and Aldosterone Antagonist Response Patterns (2018) (22)
Usefulness of preoperative C-reactive protein and soluble intercellular adhesion molecule-1 level for predicting future cardiovascular events after coronary artery bypass grafting. (2006) (22)
Influence of systolic blood pressure on clinical outcomes in elderly heart failure patients treated with nebivolol: data from the SENIORS trial (2014) (22)
Determinants of sudden cardiac death in patients with persistent atrial fibrillation in the rate control versus electrical cardioversion (RACE) study. (2006) (22)
Increased cardiovascular risk in rats with primary renal dysfunction; mediating role for vascular endothelial function (2012) (22)
Effect of right ventricular outflow tract obstruction on right ventricular volumes and exercise capacity in patients with repaired tetralogy of fallot. (2014) (22)
Predictors of left ventricular remodeling after ST-elevation myocardial infarction (2017) (21)
Circulating apoptotic proteins are increased in long-term disease-free breast cancer survivors (2006) (21)
Latent Pulmonary Vascular Disease May Alter the Response to Therapeutic Atrial Shunt Device in Heart Failure (2022) (21)
Use of natriuretic peptides for detecting cardiac dysfunction in long-term disease-free breast cancer survivors. (2005) (21)
Clinical correlates and outcome associated with changes in 6‐minute walking distance in patients with heart failure: findings from the BIOSTAT‐CHF study (2019) (21)
Comparison between felodipine and isosorbide mononitrate as adjunct to beta blockade in patients > 65 years of age with angina pectoris. (1994) (21)
Utility of Urine Neutrophil Gelatinase-Associated Lipocalin for Worsening Renal Function during Hospitalization for Acute Heart Failure: Primary Findings of the Urine N-gal Acute Kidney Injury N-gal Evaluation of Symptomatic Heart Failure Study (AKINESIS). (2019) (21)
Ischemic patterns assessed by positron emission tomography predict adverse outcome in patients with idiopathic dilated cardiomyopathy (2009) (21)
Abnormal contractile responses during dobutamine stress echocardiography in patients with idiopathic dilated cardiomyopathy. (2001) (21)
Tumour biomarkers: association with heart failure outcomes (2020) (21)
Electrophysiologic profile of ibopamine in patients with congestive heart failure and ventricular tachycardia and relation to its effects on hemodynamics and plasma catecholamines. (1991) (21)
Thirst trajectory and factors associated with persistent thirst in patients with heart failure. (2014) (20)
Treatment of heart failure with ACE inhibitors and beta-blockers (2007) (20)
Reduction of exercise-induced myocardial ischemia during add-on treatment with the angiotensin-converting enzyme inhibitor enalapril in patients with normal left ventricular function and optimal beta blockade. (2001) (20)
Determinants of Depressive Symptoms in Hospitalised Men and Women with Heart Failure (2008) (20)
A network analysis to identify pathophysiological pathways distinguishing ischaemic from non‐ischaemic heart failure (2020) (20)
Sex-related differences in risk factors, outcome, and quality of life in patients with permanent atrial fibrillation: results from the RACE II study (2019) (20)
Can critically short telomeres cause functional exhaustion of progenitor cells in postinfarction heart failure? (2007) (20)
Renal function dependent association of AGTR1 polymorphism (A1166C) and electrocardiographic left-ventricular hypertrophy. (2007) (20)
Left ventricular dilatation after myocardial infarction: ACE inhibitors, beta-blockers, or both? (1998) (20)
Effect of ibopamine on ventricular remodeling after experimental myocardial infarction: a comparison with captopril. (1994) (20)
Mode of death in patients with congestive heart failure: comparison between possible candidates for heart transplantation and patients with less advanced disease. (1993) (19)
Validity and Predictive Value of a Portable Two-Channel Sleep-Screening Tool in the Identification of Sleep Apnea in Patients With Heart Failure. (2015) (19)
Comparison between iodine 123 metaiodobenzylguanidine scintigraphy and heart rate variability for the assessment of cardiac sympathetic activity in mild to moderate heart failure. (1997) (19)
Transcatheter InterAtrial Shunt Device for the treatment of heart failure: Rationale and design of the pivotal randomized trial to REDUCE Elevated Left Atrial Pressure in Patients with Heart Failure II (REDUCE LAP-HF II). (2019) (19)
The dilemma of the strive for apoptosis in oncology: mind the heart. (2005) (19)
Integrating High-Sensitivity Troponin T and Sacubitril/Valsartan Treatment in HFpEF: The PARAGON-HF Trial. (2021) (19)
Prognostic value of renin and prorenin in heart failure patients with decreased kidney function. (2011) (19)
Evidence for differential sympathetic and parasympathetic reinnervation after heart transplantation in humans. (1997) (19)
Effect of Systolic Blood Pressure on Left Ventricular Structure and Function. (2019) (19)
beta-Adrenoceptor antagonists in elderly patients with heart failure: a critical review of their efficacy and tolerability. (2007) (19)
Effect of withdrawal of pravastatin therapy on C-reactive protein and low-density lipoprotein cholesterol. (2007) (19)
Neutrophil‐to‐lymphocyte ratio and outcomes in patients with new‐onset or worsening heart failure with reduced and preserved ejection fraction (2021) (19)
Impact of mitral regurgitation in patients with worsening heart failure: insights from BIOSTAT‐CHF (2021) (19)
Incidence and Outcomes of Pneumonia in Patients With Heart Failure. (2021) (19)
Epicardial Adipose Tissue and Outcome in Heart Failure With Mid-Range and Preserved Ejection Fraction (2021) (18)
Vascular Function and Mild Renal Impairment in Stable Coronary Artery Disease (2005) (18)
Pregnancy after biventricular repair for pulmonary atresia with ventricular septal defect. (2006) (18)
Targeted therapy of underlying conditions improves quality of life in patients with persistent atrial fibrillation: results of the RACE 3 study. (2019) (18)
Effect on mode of death of heart failure treatment started with bisoprolol followed by Enalapril, compared to the opposite order: results of the randomized CIBIS III trial. (2011) (18)
Vascular effects of quinapril completely depend on ACE insertion/deletion polymorphism (2004) (18)
Is anemia in chronic heart failure caused by iron deficiency? (2007) (18)
Frequency of and Prognostic Significance of Cardiac Involvement at Presentation in Hereditary Transthyretin-Derived Amyloidosis and the Value of N-Terminal Pro-B-Type Natriuretic Peptide. (2018) (18)
Natriuretic Peptide-Based Inclusion Criteria in a Heart Failure Clinical Trial: Insights From COMMANDER HF. (2020) (18)
Systolic blood pressure reduction during the first 24 h in acute heart failure admission: friend or foe? (2018) (18)
An economic evaluation of rosuvastatin treatment in systolic heart failure: evidence from the CORONA trial (2010) (18)
Trajectory of self-care behaviour in patients with heart failure: the impact on clinical outcomes and influencing factors (2020) (18)
Telemonitoring of outpatients with heart failure: a search for the holy grail? (2012) (18)
Beta-blocker titration failure is independent of severity of heart failure. (2000) (18)
Proenkephalin, an Opioid System Surrogate, as a Novel Comprehensive Renal Marker in Heart Failure. (2019) (18)
Effectiveness of beta-blocker therapy in daily practice patients with advanced chronic heart failure; is there an effect-modification by age? (2007) (18)
Distinct Pathological Pathways in Patients With Heart Failure and Diabetes. (2020) (18)
The enigma of quality of life in patients with heart failure. (2008) (18)
Usefulness of heart rate variability in predicting drug efficacy (metoprolol vs diltiazem) in patients with stable angina pectoris. (1995) (18)
Low-dose digoxin in patients with heart failure. Less toxic and at least as effective? (2002) (18)
Nuclear hormone receptors as regulators of the renin-angiotensin-aldosterone system. (2008) (18)
The role of cathepsin D in the pathophysiology of heart failure and its potentially beneficial properties: a translational approach (2019) (17)
Relation between myocardial beta-adrenoceptor density and hemodynamic and neurohumoral changes in a rat model of chronic myocardial infarction: effects of ibopamine and captopril. (1995) (17)
Efficacy of Angiotensin II Type 1 Receptor Blockade on Reperfusion-Induced Arrhythmias and Mortality Early After Myocardial Infarction Is Increased in Transgenic Rats With Cardiac Angiotensin II Type 1 Overexpression (2002) (17)
Effects of dopaminergic agents on cardiac and renal function in normal man and in patients with congestive heart failure. (1992) (17)
Dose-finding study of imidapril, a novel angiotensin converting enzyme inhibitor, in patients with stable chronic heart failure (1996) (17)
Renal function as a predictor of prognosis in chronic heart failure. (2002) (17)
Fertility, Pregnancy and Delivery in Women after Biventricular Repair for Double Outlet Right Ventricle (2007) (17)
Blockade of the renin angiotensin system in heart failure: the potential place of angiotensin II receptor blockers. (2000) (17)
Electrocardiographic patterns relative to initiating mechanisms of exercise-induced ventricular tachycardia. (1993) (17)
Quality of life in men and women with heart failure: association with outcome, and comparison between the Kansas City Cardiomyopathy Questionnaire and the EuroQol 5 dimensions questionnaire (2021) (16)
Effect of continuous versus episodic amiodarone treatment on quality of life in persistent atrial fibrillation. (2010) (16)
Iron Deficiency in Heart Failure: Mechanisms and Pathophysiology (2021) (16)
Pregnancy in women with pre-existent ischaemic heart disease: a systematic review with individualised patient data (2019) (16)
Clinical outcomes according to QRS duration and morphology in the Eplerenone in Mild Patients: Hospitalization and SurvIval Study in Heart Failure (EMPHASIS‐HF) (2015) (16)
[Telomeres and biological ageing in cardiovascular disease]. (2008) (16)
Erythropoietin levels in heart failure after an acute myocardial infarction: determinants, prognostic value, and the effects of captopril versus losartan. (2009) (16)
Coronary angiography in worsening heart failure: determinants, findings and prognostic implications (2017) (16)
The Effect of Metformin on Diastolic Function in Patients Presenting with ST-Elevation Myocardial Infarction (2016) (16)
A randomised controlled trial of cardiac rehabilitation after revascularisation. (2007) (16)
Genome-wide studies of heart failure and endophenotypes: lessons learned and future directions (2018) (16)
Polymorphisms of adrenoceptors are not associated with an increased risk of adverse event in heart failure: a MERIT-HF substudy. (2009) (16)
Relationship between angina pectoris and outcomes in patients with heart failure and reduced ejection fraction: an analysis of the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). (2014) (16)
Expanding the concept of telomere dysfunction in cardiovascular disease. (2008) (16)
[Research set-up concerning the effectiveness of heart failure clinics in the Netherlands]. (2003) (16)
Endothelial dysfunction and reduced myocardial perfusion reserve in heart failure secondary to coronary artery disease. (2003) (15)
Hemoglobin levels and new-onset heart failure in the community. (2015) (15)
Pathophysiology of vascular endothelium and circulating platelets: implications for coronary revascularisation and treatment. (2001) (15)
High-sensitivity C-reactive protein and long term reperfusion success of primary percutaneous intervention in ST-elevation myocardial infarction. (2017) (15)
A Clinical Tool to Predict Low Serum Selenium in Patients with Worsening Heart Failure (2020) (15)
Planning and monitoring of placebo-controlled survival trials: comparison of the triangular test with usual interim analyses methods. (2003) (15)
Fertility, pregnancy, and delivery after biventricular repair for pulmonary atresia with an intact ventricular septum. (2006) (15)
Effects of lacidipine on peak oxygen consumption, neurohormones and invasive haemodynamics in patients with mild to moderate chronic heart failure. (1996) (15)
Maternal right ventricular function, uteroplacental circulation in first trimester and pregnancy outcome in women with congenital heart disease (2019) (15)
Association between prehospital delay and subsequent clinical course in patients with/hospitalized for heart failure. (2012) (15)
Heart rate and outcome in heart failure with reduced ejection fraction: Differences between atrial fibrillation and sinus rhythm—A CIBIS II analysis (2017) (15)
Bariatric surgery and cardiovascular disease: a systematic review and meta-analysis (2022) (15)
Chronic ischemic mitral regurgitation and papillary muscle infarction detected by late gadolinium-enhanced cardiac magnetic resonance imaging in patients with ST-segment elevation myocardial infarction (2016) (15)
Pregnancy in women with corrected aortic coarctation: Uteroplacental Doppler flow and pregnancy outcome. (2017) (15)
Higher doses of loop diuretics limit uptitration of angiotensin-converting enzyme inhibitors in patients with heart failure and reduced ejection fraction (2020) (15)
Effect of Metformin on Metabolites and Relation With Myocardial Infarct Size and Left Ventricular Ejection Fraction After Myocardial Infarction (2017) (15)
Predictors of Angiotensin-Converting Enzyme Inhibitor–Induced Reduction of Urinary Albumin Excretion in Nondiabetic Patients (2006) (15)
High serum erythropoietin levels are related to heart failure development in subjects from the general population with albuminuria: data from PREVEND (2016) (15)
Aspirin does not reduce the clinical benefits of the mineralocorticoid receptor antagonist eplerenone in patients with systolic heart failure and mild symptoms: an analysis of the EMPHASIS‐HF study (2016) (14)
Dietary sodium restriction specifically potentiates left ventricular ACE inhibition by zofenopril, and is associated with attenuated hypertrophic response in rats with myocardial infarction (2004) (14)
Impairment of myocardial blood flow reserve in patients with asymptomatic left ventricular dysfunction: Effects of ACE-inhibition with perindopril (2001) (14)
The contribution of observational studies to the knowledge of drug effectiveness in heart failure. (2007) (14)
Both antiplatelet and anticoagulant therapy may favorably affect outcome in patients with advanced heart failure. A retrospective analysis of the PRIME-II trial. (2005) (14)
Nitrate administration increases blood flow in dysfunctional but viable myocardium, leading to improved assessment of myocardial viability: A PET study. (2006) (14)
Long-term changes in renal function and perfusion in heart failure patients with reduced ejection fraction (2015) (14)
Erythropoietin in chronic heart failure. (2007) (14)
Different effects of bisoprolol on heart rate in patients with ischemic or idiopathic dilated cardiomyopathy (a 24-hour Holter substudy of the Cardiac Insufficiency Bisoprolol Study [CIBIS]). (1999) (14)
Impairment of exercise capacity and peak oxygen consumption in patients with mild left ventricular dysfunction and coronary artery disease. (1998) (14)
The feasibility of repeated left ventricular ejection fraction analysis with sequential single-dose radionuclide ventriculography (2005) (13)
Importance of epicardial adipose tissue localization using cardiac magnetic resonance imaging in patients with heart failure with mid‐range and preserved ejection fraction (2021) (13)
The role of coronary endothelial function testing in patients suspected for angina pectoris. (2004) (13)
Peripartum cardiomyopathy: Euro Observational Research Program (2014) (13)
Effects of Ibopamine on Exercise-Induced Increase in Norepinephrine in Normal Men (1992) (13)
Association of Circulating Ketone Bodies With Functional Outcomes After ST-Segment Elevation Myocardial Infarction. (2021) (13)
Biological versus mechanical heart valve prosthesis during pregnancy in women with congenital heart disease. (2018) (13)
Measurement of myocardial β-adrenoceptor density in clinical studies: a role for positron emission tomography? (2001) (13)
Progression of mild untreated heart failure during six months follow-up and clinical and neurohumoral effects of ibopamine and digoxin as monotherapy. DIMT Study Group. Dutch Ibopamine Multicenter Trial. (1995) (13)
Identification of a specific pattern of downregulation in expression of isoforms of vascular endothelial growth factor in dilated cardiomyopathy (2002) (13)
Geographical differences in heart failure characteristics and treatment across Europe: results from the BIOSTAT-CHF study (2020) (12)
Effects of ibopamine on renal haemodynamics in patients with severe congestive heart failure. (1993) (12)
Diabetes Mellitus and Right Ventricular Dysfunction in Heart Failure With Preserved Ejection Fraction. (2017) (12)
Hydrochlorothiazide increases plasma or tissue angiotensin-converting enzyme-inhibitor drug levels in rats with myocardial infarction: differential effects on lisinopril and zofenopril. (2005) (12)
Effects of ibopamine on the increase in plasma norepinephrine levels during exercise in congestive heart failure. (1993) (12)
Erythropoietin in cardiovascular diseases: exploring new avenues. (2008) (12)
Plasma D‐dimer concentrations predicting stroke risk and rivaroxaban benefit in patients with heart failure and sinus rhythm: an analysis from the COMMANDER‐HF trial (2020) (12)
Heart failure etiologies and clinical factors precipitating for worsening heart failure: Findings from BIOSTAT-CHF. (2019) (12)
Associations of Body Mass Index With Laboratory and Biomarkers in Patients With Acute Heart Failure (2017) (12)
Heart rate variability in patients with mild to moderate heart failure: effects of neurohormonal modulation by digoxin and ibopamine. The Dutch Ibopamine Multicenter Trial (DIMT) Study Group. (1995) (12)
A comparison of the prognostic value of BNP versus NT-proBNP after hospitalisation for heart failure (2018) (12)
Evaluation of right ventricular function by NuSMUGA software: gated blood-pool SPECT vs. first-pass radionuclide angiography (2003) (12)
Acute heart failure in the young: Clinical characteristics and biomarker profiles. (2016) (11)
Serum potassium and outcomes in heart failure with preserved ejection fraction: a post‐hoc analysis of the PARAGON‐HF trial (2021) (11)
Natriuresis‐guided therapy in acute heart failure: rationale and design of the Pragmatic Urinary Sodium‐based treatment algoritHm in Acute Heart Failure (PUSH‐AHF) trial (2021) (11)
Cardiotoxicity of breast cancer treatment: no easy solution for an important long-term problem. (2016) (11)
Safety and Tolerability of Sodium Thiosulfate in Patients with an Acute Coronary Syndrome Undergoing Coronary Angiography: A Dose-Escalation Safety Pilot Study (SAFE-ACS) (2020) (11)
Diabetes and pre‐diabetes in patients with heart failure and preserved ejection fraction (2021) (11)
Prognostic significance of changes in heart rate following uptitration of beta-blockers in patients with sub-optimally treated heart failure with reduced ejection fraction in sinus rhythm versus atrial fibrillation (2019) (11)
Effect of Metformin Treatment on Lipoprotein Subfractions in Non-Diabetic Patients with Acute Myocardial Infarction: A Glycometabolic Intervention as Adjunct to Primary Coronary Intervention in ST Elevation Myocardial Infarction (GIPS-III) Trial (2016) (11)
Effects of C-reactive protein and cholesterol on responsiveness in vitro of the internal thoracic artery to angiotensin II in patients having coronary artery bypass grafting. (2006) (11)
Clinical and autonomic effects of ibopamine as adjunct to angiotensin-converting enzyme inhibitors in chronic heart failure. (1996) (11)
Vitamin D supplementation in heart failure: case closed? (2017) (11)
New developments in the pharmacotherapeutic management of heart failure in elderly patients: concerns and considerations (2017) (11)
Role of angiotensin receptor blockers in patients with left ventricular dysfunction: lessons from CHARM and VALIANT. (2004) (11)
Non‐adherence to heart failure medications predicts clinical outcomes: assessment in a single spot urine sample by liquid chromatography‐tandem mass spectrometry (results of a prospective multicentre study) (2021) (11)
The impact of coronary artery disease risk loci on ischemic heart failure severity and prognosis: association analysis in the COntrolled ROsuvastatin multiNAtional trial in heart failure (CORONA) (2014) (11)
High-Sensitivity Troponin-T and Cardiovascular Outcomes in the Community: Differences Between Women and Men. (2020) (11)
Reversion of tachycardiomyopathy after beta-blocker. (1993) (11)
Low pulse pressure as a poor-man's indicator of a low cardiac index in patients with severe cardiac dysfunction (2014) (10)
Atrial Natriuretic Peptides During Experimental Atrial Tachycardia: (2004) (10)
Cardiovascular abnormalities in patients with a carcinoid syndrome. (2002) (10)
The bidirectional interaction between atrial fibrillation and heart failure: consequences for the management of both diseases (2021) (10)
Leukocyte telomere length and left ventricular function after acute ST-elevation myocardial infarction: data from the glycometabolic intervention as adjunct to primary coronary intervention in ST elevation myocardial infarction (GIPS-III) trial (2015) (10)
Relationship between body mass index, cardiovascular biomarkers and incident heart failure (2021) (10)
Anaemia of chronic disease in chronic heart failure: the emerging evidence. (2005) (10)
Anaemia and renal dysfunction in chronic heart failure (2009) (10)
A genotype‐directed comparative effectiveness trial of Bucindolol and metoprolol succinate for prevention of symptomatic atrial fibrillation/atrial flutter in patients with heart failure: Rationale and design of the GENETIC‐AF trial (2017) (10)
Renal and Systemic Hemodynamic Effects of Ibopamine in Patients with Mild to Moderate Congestive Heart Failure (1995) (10)
Angiotensin II Type 2 Receptor Vasoactivity in Internal Mammary Arteries of Patients With Coronary Artery Disease (2007) (10)
Clinical and neurohumoral differences between spirapril and captopril in mild to moderate chronic congestive heart failure. (1997) (10)
Autonomic and hemodynamic effects of a new selective dopamine agonist, CHF1035, in patients with chronic heart failure (2001) (10)
Alterations in the Prognosis of Chronic Heart Failure: An Overview of the Major Mortality Trials (1997) (10)
Hyporesponsiveness to Darbepoetin Alfa in Patients With Heart Failure and Anemia in the RED-HF Study (Reduction of Events by Darbepoetin Alfa in Heart Failure): Clinical and Prognostic Associations (2018) (10)
Identifying Subpopulations with Distinct Response to Treatment Using Plasma Biomarkers in Acute Heart Failure: Results from the PROTECT Trial (2017) (10)
The optimal "dose" of disease management programs in HF. (2002) (10)
Telomere length and outcome in heart failure (2008) (9)
Treatment of anemia with darbepoetin alfa in heart failure. (2010) (9)
Myocardial perfusion reserve and contractile pattern after beta-blocker therapy in patients with idiopathic dilated cardiomyopathy (2010) (9)
Functional Antagonism of Different Angiotensin II Type I Receptor Blockers in Human Arteries (2002) (9)
Dopaminergic modulation of physiological and pathological neurohumoral activation in man. (1995) (9)
Improved Cardiac MRI Volume Measurements in Patients with Tetralogy of Fallot by Independent End-Systolic and End-Diastolic Phase Selection (2013) (9)
Micronutrient deficiencies in heart failure: Mitochondrial dysfunction as a common pathophysiological mechanism? (2022) (9)
Troponin I, troponin T, and creatine kinase-MB mass in patients with the carcinoid syndrome with and without heart failure. (1999) (9)
Surviving the first COVID‐19 wave and learning lessons for the second (2020) (9)
The relation between soluble apoptotic proteins and subclinical cardiotoxicity in adjuvant-treated breast cancer patients. (2006) (9)
Efficacy and safety of ibopamine in congestive heart failure. (1990) (9)
The effect of treatment with bisoprolol-first versus enalapril-first on cardiac structure and function in heart failure. (2010) (9)
Gated blood-pool SPECT automated versus manual left ventricular function calculations (2004) (9)
Short-term statin therapy and cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. (2004) (9)
Effect of Metformin on Renal Function After Primary Percutaneous Coronary Intervention in Patients Without Diabetes Presenting with ST-elevation Myocardial Infarction: Data from the GIPS-III Trial (2015) (9)
Difference in long-term prognostic value of renal function between ischemic and non-ischemic mild heart failure. (2006) (8)
Health status improvement with ferric carboxymaltose in heart failure with reduced ejection fraction and iron deficiency (2022) (8)
Changes of neurohumoral parameters and endothelin-1 in response to exercise in patients with mild to moderate congestive heart failure. (1998) (8)
The value of spot urinary creatinine as a marker of muscle wasting in patients with new‐onset or worsening heart failure (2021) (8)
Genetic risk and atrial fibrillation in patients with heart failure (2020) (8)
Intensive versus moderate lipid lowering with statins after acute coronary syndromes. (2004) (8)
Electrophysiological changes of angiotensin-converting enzyme inhibition after myocardial infarction. (2000) (8)
Anaemia predicts cardiovascular events in patients with stable coronary artery disease. (2005) (8)
Sacubitril/Valsartan and Frailty in Patients With Heart Failure and Preserved Ejection Fraction. (2022) (8)
Effects of amlodipine on endothelial function in rats with chronic heart failure after experimental myocardial infarction. (1997) (8)
Renal and neurohumoral effects of ibopamine and metoclopramide in normal man. (1991) (8)
Direct interaction between the sympathetic and renin-angiotensin system in myocardial tissue: a microdialysis study in anaesthetised rats. (2000) (8)
Optimal treatment of underlying conditions improves rhythm control outcome in atrial fibrillation - Data from RACE 3. (2020) (8)
Right atrial overdrive pacing for prevention of symptomatic refractory atrial fibrillation. (2006) (8)
Direct vasodilating effects of the new dopaminergic agonist Z1046 in human arteries. (2000) (7)
What should the C (‘congestive heart failure’) represent in the CHA2DS2‐VASc score? (2020) (7)
Early pharmacologic intervention may prevent the deterioration in endothelial function after experimental myocardial infarction in rats: effects of ibopamine and captopril. (1997) (7)
Dipeptidyl peptidase 3, a marker of the antagonist pathway of the renin–angiotensin–aldosterone system in patients with heart failure (2021) (7)
Value of digoxin in patients with heart failure: new pieces to the puzzle (2018) (7)
[Adherence to guidelines in CHF therapy in Germany]. (2005) (7)
Acute hemodynamic and long-term clinical effects of isradipine in patients with coronary artery disease and chronic heart failure. A double-blind, placebo-controlled study. (1996) (7)
Rationale and design of the PHOspholamban RElated CArdiomyopathy intervention STudy (i-PHORECAST) (2021) (7)
Visit-to-visit blood pressure variation and outcomes in heart failure with reduced ejection fraction: findings from the Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms trial. (2020) (7)
Antiarrhythmic drugs in patients with early persistent atrial fibrillation and heart failure: results of the RACE 3 study (2021) (7)
Differences in biomarkers and molecular pathways according to age for patients with HFrEF. (2020) (7)
Right ventricular dysfunction in heart failure with reduced vs. preserved ejection fraction: non‐identical twins? (2017) (7)
Asialoerythropoietin to protect the failing heart: is it possible to run with the hare and hunt with the hounds? (2010) (7)
Cardiorenal effects of recombinant human natriuretic peptides. (2010) (7)
Thoracoscopic monitoring for pericardial application of local drug or gene therapy. (2002) (7)
Pharmacogenetics in heart failure: promises and challenges (2009) (7)
The erythropoietin receptor expressed in skeletal muscle is essential for mitochondrial biogenesis and physiological exercise (2021) (7)
High Angiotensin II Responsiveness is Associated with Decreased Endothelium-Dependent Relaxation in Human Arteries (2005) (7)
Sex‐Based Differences in Unrecognized Myocardial Infarction (2020) (7)
Global Differences in Heart Failure With Preserved Ejection Fraction (2021) (6)
Myocardial infarction with aortic banding. A combined rat model of heart failure. (1997) (6)
Effects of Spirapril and Captopril on Regional Blood Flow in Chronic Congestive Heart Failure: A Comparison Between a Short- and a Long‐Acting Angiotensin‐Converting Enzyme Inhibitor (1995) (6)
Broad complex tachycardia during treatment of atrial fibrillation with a 1c antiarrhythmic drug: ventricular or supraventricular proarrhythmia? (2006) (6)
Decreased Mortality With Beta-Blockers in Patients With Heart Failure and Coexisting Atrial Fibrillation. (2017) (6)
Effect of lower body negative pressure in patients with mild congestive heart failure. (2003) (6)
Relation of Decongestion and Time to Diuretics to Biomarker Changes and Outcomes in Acute Heart Failure. (2021) (6)
The clinical and prognostic value of late Gadolinium enhancement imaging in heart failure with mid-range and preserved ejection fraction (2021) (6)
Effect of mibefradil on heart rate variability in patients with chronic heart failure. (2000) (6)
Dosing of ACE inhibitors in left ventricular dysfunction: does current clinical dosing provide optimal benefit? (1999) (6)
Impact of Geographic Region on the COMMANDER-HF Trial. (2020) (6)
Left atrial volume and left ventricular mass indices in heart failure with preserved and reduced ejection fraction (2021) (6)
NHF-COACH multicenter trial in The Netherlands: searching for underlying potentially beneficial mechanisms in nurse led heart failure management. (2002) (6)
N‐terminal pro‐B‐type natriuretic peptide and prognosis in Caucasian vs. Asian patients with heart failure (2018) (6)
Aldosterone blockade in post‐acute myocardial infarction heart failure (2006) (6)
Beta-adrenoceptor density in chronic infarcted myocardium: a subtype specific decrease of beta1-adrenoceptor density. (2000) (6)
New data on soluble ACE2 in patients with atrial fibrillation reveal potential value for treatment of patients with COVID-19 and cardiovascular disease (2020) (6)
Vagal nerve stimulation for heart failure: new pieces to the puzzle? (2015) (6)
Role of echocardiography in the diagnosis of cardiac lymphoma. (1990) (6)
Outcome of pharmacological rhythm control for new-onset persistent atrial fibrillation in patients with systolic heart failure: a comparison with patients with normal left ventricular function. (2007) (6)
The pharmacological management of heart failure: too many treatments? (2003) (5)
Relative fat mass, a new index of adiposity, is strongly associated with incident heart failure: data from PREVEND (2022) (5)
[New dopamine agonists in cardiovascular therapy]. (1992) (5)
Rapid progression of pericardial malignant mesothelioma (1998) (5)
Noninvasive haemodynamic monitoring using finger arterial pressure waveforms. (2009) (5)
Effect of Isradipine and Nifedipine on Diastolic Function in Patients with Left Ventricular Dysfunction Due to Coronary Artery Disease: A Randomized, Double‐Blind, Nuclear, Stethoscope Study (1994) (5)
Using matrix assisted laser desorption ionisation mass spectrometry (MALDI-MS) profiling in order to predict clinical outcomes of patients with heart failure (2018) (5)
Changes in Appetite During the Heart Failure Trajectory and Association With Fatigue, Depressive Symptoms, and Quality of Life. (2020) (5)
T cell and monocyte/macrophage activation markers associate with adverse outcome, but give limited prognostic value in anemic patients with heart failure: results from RED-HF (2018) (5)
Inflammation and remodeling pathways and risk of cardiovascular events in patients with ischemic heart failure and reduced ejection fraction (2022) (5)
Eptifibatide and Abciximab Exhibit Equivalent Antiplatelet Efficacy in an Experimental Model of Stenting in Both Healthy Volunteers and Patients with Coronary Artery Disease (2001) (5)
Safety and clinical outcome of erythropoiesis-stimulating agents in patients with ST-elevation myocardial infarction: a meta-analysis of individual patient data. (2014) (5)
Nebivolol in chronic heart failure: current evidence and future perspectives (2010) (5)
Mortality and preoperative cardiac function in vascular amputees: an N-terminal pro-brain natriuretic peptide (NT-proBNP) pilot study (2008) (5)
GENETIC-AF: Bucindolol for the Maintenance of Sinus Rhythm in a Genotype-Defined Heart Failure Population. (2019) (5)
Serum erythropoietin levels and infarct size. (2006) (5)
New oral anticoagulants in heart failure (2013) (5)
Impaired High‐Density Lipoprotein Function in Patients With Heart Failure (2020) (5)
Serial right ventricular endomyocardial biopsy in rapid-onset severe heart failure due to giant cell myocarditis. (2006) (5)
Rationale and Design of the Groningen Intervention Study for the Preservation of Cardiac Function with Sodium Thiosulfate after ST-segment Elevation Myocardial Infarction (GIPS-IV) Trial. (2021) (5)
Measuring Pulmonary Artery Pressures in Heart Failure: A New Useful Diagnostic Tool? (2017) (5)
Clinical impact of changes in mitral regurgitation severity after medical therapy optimization in heart failure (2022) (5)
Effects of rosuvastatin on coronary flow reserve and metabolic mismatch in patients with heart failure (from the CORONA Study). (2010) (5)
Right ventricular dysfunction in patients with new‐onset heart failure: longitudinal follow‐up during guideline‐directed medical therapy (2022) (4)
Dapagliflozin effect on heart failure with prevalent or new‐onset atrial fibrillation (2022) (4)
Clinical implications of low estimated protein intake in patients with heart failure (2022) (4)
Review: The revised role of ACE-inhibition after myocardial infarction in the thrombolytic/primary PCI era (2004) (4)
The effects of ibopamine on glomerular filtration rate and plasma norepinephrine remain preserved during prolonged treatment in patients with congestive heart failure. (1995) (4)
Impact of Chronic Obstructive Pulmonary Disease in Patients With Heart Failure With Preserved Ejection Fraction: Insights From PARAGON‐HF (2021) (4)
Acute coronary syndromes: the unfulfilled promise of erythropoietin in patients with MI. (2011) (4)
Heart failure patients' future expectations and their association with disease severity, quality of life, depressive symptoms and clinical outcomes (2016) (4)
Rapid right-sided deterioration in heart failure with preserved ejection fraction (2019) (4)
Diversity in management of heart failure patients. (2006) (4)
Heart failure re-hospitalizations and subsequent fatal events in coronary artery disease: insights from COMMANDER-HF, EPHESUS, and EXAMINE (2021) (4)
Residual confounding in observational studies: new data from the old DIG trial. (2019) (4)
ACE-inhibitors, Beta-blockers or the Combination in Heart Failure: Is It Just an A–B–C ? (2008) (4)
Secondary prevention in coronary heart disease patients with low HDL: which options do we have? (2003) (4)
Agreement of 2D transthoracic echocardiography with cardiovascular magnetic resonance imaging after ST-elevation myocardial infarction. (2019) (4)
Additional burden of iron deficiency in heart failure patients beyond the cardio‐renal anaemia syndrome: findings from the BIOSTAT‐CHF study (2021) (4)
Clinical determinants and prognostic implications of renin and aldosterone in patients with symptomatic heart failure (2020) (4)
Improvement in left ventricular ejection fraction after pharmacological up-titration in new-onset heart failure with reduced ejection fraction (2021) (4)
Distinct pathophysiological pathways in women and men with heart failure (2022) (4)
Predictors of non-pharmacological intervention in patients with paroxysmal atrial fibrillation: Value of neuroticism. (2006) (4)
Vasopeptidase inhibition in heart failure. (2000) (4)
Surrogate markers of gut dysfunction are related to heart failure severity and outcome - from the BIOSTAT-CHF consortium. (2022) (4)
Erythropoiesis-stimulating agents and heart failure. (2011) (4)
Doppler gradients, valve area and ventricular function in pregnant women with aortic or pulmonary valve disease: Left versus right. (2019) (4)
Exploratory Study of the Effects of Single Doses of Isomazole on Hemodynamics and Heart Rate Variability Parameters in Chronic Heart Failure (1995) (4)
Albuminuria as a marker of systemic congestion in patients with heart failure (2022) (4)
Hemodynamic and autonomic effects of intravenous saterinone in patients with chronic heart failure. (1997) (3)
Psychology and cardiology: do not forget the heart failure patient. (2008) (3)
[Arrhythmogenic right-ventricular cardiomyopathy: different manifestations as precursors of sudden death which might be prevented]. (2004) (3)
Multimarker profiling identifies protective and harmful immune processes in heart failure: findings from BIOSTAT-CHF (2021) (3)
Longitudinal changes in circulating ketone body levels in patients with acute heart failure: A post-hoc analysis of the EMPA-Response-AHF Trial. (2022) (3)
Decongestion, kidney injury and prognosis in patients with acute heart failure. (2022) (3)
Pharmacotherapy for comorbidities in chronic heart failure: a focus on hematinic deficiencies, diabetes mellitus and hyperkalemia (2016) (3)
Pathophysiologic Processes and Novel Biomarkers Associated With Congestion in Heart Failure. (2022) (3)
Radiofrequency ablation of atrial fibrillation. (2004) (3)
Effects of selective dopaminergic receptor stimulation on ventricular remodeling after experimental myocardial infarction in rats. (1997) (3)
Fibroblast growth factor 23 mediates the association between iron deficiency and mortality in worsening heart failure (2020) (3)
Connecting epicardial adipose tissue and heart failure with preserved ejection fraction: mechanisms, management and modern perspectives (2022) (3)
Triggered activity as arrhythmogenic mechanism after myocardial infarction: Clinical and electrophysiologic study of one case (1992) (3)
Whole blood transcriptomic profiling identifies molecular pathways related to cardiovascular mortality in heart failure (2022) (3)
Pathophysiological pathways related to high plasma growth differentiation factor 15 concentrations in patients with heart failure (2022) (3)
Psychological distress and cardiovascular disease. (2005) (3)
Investigator-reported ventricular arrhythmias and mortality in heart failure with mildly reduced or preserved ejection fraction. (2023) (3)
Guidelines for atrial fibrillation in heart failure need to be clarified. (2010) (3)
Pathophysiological pathways in patients with heart failure and atrial fibrillation (2021) (3)
[Carbon monoxide poisoning as a trigger for myocardial infarction]. (1993) (3)
Atrial natriuretic peptide in atrial fibrillation: a protective but time-limited system. (2002) (3)
Early N-terminal pro-B-type natriuretic peptide is associated with cardiac complications and function during pregnancy in congenital heart disease (2021) (3)
[The nurse practitioner in the treatment of cardiac patients: successful job reallocation within health care]. (2006) (3)
Responder analysis for improvement in 6‐min walk test with ferric carboxymaltose in patients with heart failure with reduced ejection fraction and iron deficiency (2022) (3)
The oral dopamine agonist, ibopamine, in normal man: effects on rhythm, heart rate, blood pressure and catecholamines. (1991) (3)
The Additive Prognostic Value of Serial Plasma Interleukin-6 Levels over Changes in Brain Natriuretic Peptide in Patients with Acute Heart Failure. (2021) (3)
New-onset atrial fibrillation in patients with worsening heart failure and coronary artery disease: an analysis from the COMMANDER-HF trial (2021) (3)
Validation of Fick cardiac output calculated with assumed oxygen consumption: a study of cardiac output during epoprostenol. (2004) (3)
Biodistribution and pharmacokinetics of radiolabeled trastuzumab in HER2-positive metastatic breast cancer. (2004) (3)
Factor Xa Inhibition with Apixaban Does Not Influence Cardiac Remodelling in Rats with Heart Failure After Myocardial Infarction (2020) (3)
Measurement of myocardial beta-adrenoceptor density in clinical studies: a role for positron emission tomography? (2002) (3)
Pregnancy unbosoms the heart of breast cancer survivors. (2012) (3)
Circulating apoptosis-related proteins in long-term disease free breast cancer survivors. (2004) (3)
Reduced right ventricular function on cardiovascular magnetic resonance imaging is associated with uteroplacental impairment in tetralogy of Fallot (2020) (3)
Prognostic value of pulse pressure in heart failure. (2007) (3)
Cardiac resynchronization therapy improves renal function: importance of forward and backward failure. (2009) (3)
Cardiovascular Determinants of Impaired Placental Function in Women with Cardiac Dysfunction. (2021) (3)
Myocardial ischaemia with a normal coronary angiogram due to the primary antiphospholipid syndrome. (2002) (3)
The value of echocardiographic measurement of epicardial adipose tissue in heart failure patients (2022) (3)
Progress in heart failure management in the Netherlands and beyond: long-term commitment to deliver high-quality research and patient care (2020) (2)
To bind or not to bind: potassium-lowering drugs in heart failure. (2011) (2)
A deleterious interaction between omecamtiv mecarbil and atrial fibrillation in patients with heart failure: an influence of digoxin? (2022) (2)
Impact of Insulin Treatment on the Effect of Eplerenone: Insights From the EMPHASIS-HF Trial (2021) (2)
Heart failure, atrial fibrillation, and beta-blockers. (2005) (2)
Beta-blocker treatment before angiotensin-converting enzyme inhibitor therapy in newly diagnosed heart failure. (2005) (2)
Bucindolol Decreases Atrial Fibrillation Burden in Patients With Heart Failure and the ADRB1 Arg389Arg Genotype (2021) (2)
Comorbidities complicating heart failure: changes over the last 15 years (2022) (2)
Minimal Clinically Important Difference for Six-minute Walk Test in Patients with HFrEF and Iron Deficiency. (2022) (2)
Clinical implications of left atrial changes after optimization of medical therapy in patients with heart failure (2022) (2)
Effects of a simple cardiac rehabilitation program on improvement of self-reported physical activity in atrial fibrillation – Data from the RACE 3 study (2020) (2)
Cardiac resynchronization therapy in chronic heart failure: how to select the patient that will benefit? (2005) (2)
Nuclear cardiac imaging for the assessment of myocardial viability. (2005) (2)
Interethnic analyses of blood pressure loci in populations of East Asian and European descent (2018) (2)
Angiotensin-converting enzyme inhibitors and outcome among patients with heart failure and renal insufficiency: need for a prospective study. (2005) (2)
Effect of fosinopril treatment on serum C-reactive protein levels in patients with microalbuminuria. (2008) (2)
Dopamine agonists, a new perspective in cardiovascular therapy? (1991) (2)
Low-dose digoxin in heart failure. (2009) (2)
Letter by de Boer and van Veldhuisen regarding article, "Risk of thromboembolism in heart failure: an analysis from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT)". (2008) (2)
Assessment of trastuzumab-related cardiac dysfunction in the Herceptin Adjuvant (HERA) Trial with 3.6 years median follow- up. (2009) (2)
Cardiac Transthyretin-derived Amyloidosis: An Emerging Target in Heart Failure with Preserved Ejection Fraction? (2019) (2)
Preoperative cardiac screening using NT-proBNP in obese patients 50 years and older undergoing bariatric surgery: a study of 310 consecutive patients† (2020) (2)
Pharmacological treatment of chronic heart failure according to the 2005 guidelines of the European Society of Cardiology. (2005) (2)
Influence of renal dysfunction on the pharmacokinetics of the selective Na+/H+ exchange inhibitor EMD 87 580 in patients with chronic heart failure. (2005) (2)
Heart rates in cardiac resynchronization: the art of optimal device programming. (2011) (2)
[Partial left ventriculectomy (Batista procedure) for the treatment of terminal heart failure after rejection for heart transplantation]. (1999) (2)
Causal Pathways from Blood Pressure to Larger QRS Amplitudes: a Mendelian Randomization Study (2018) (2)
Anemia is associated with an increased central venous pressure and mortality in a broad spectrum of cardiovascular patients (2014) (2)
Erythropoiesis stimulation in acute ischemic syndromes. (2010) (2)
56 Poster Moderated Innovative ICT Guided Disease Management and Telemonitoring in out Patient Clinics for Chronic Heart Failure Patients (In Touch Study Design) a Disease Management Study with Patient Oriented Outcomes (2010) (2)
Genetics in heart failure: where are we headed? (2006) (2)
Growth differentiation factor 15 predicts poor prognosis in patients with heart failure and reduced ejection fraction and anemia: results from RED-HF (2021) (2)
Late onset cardiomyopathy as presenting sign of ATTR A45G amyloidosis caused by a novel TTR mutation (p.A65G). (2017) (2)
Letter by Huzen et al regarding article, "Association of leukocyte telomere length with circulating biomarkers of the renin-angiotensin-aldosterone system: the Framingham Heart Study". (2008) (2)
Type D Personality as a Risk Factor for Adverse Outcome in Patients With Cardiovascular Disease: An Individual Patient-Data Meta-analysis (2021) (2)
Six-minute walk test: prognostic value and effects of nebivolol versus placebo in elderly patients with heart failure from the SENIORS trial (2020) (1)
Downgrade of cardiac defibrillator devices to pacemakers in elderly heart failure patients: clinical considerations and the importance of shared decision-making (2021) (1)
Telomere length is independently associated with all-cause mortality in chronic heart failure (2021) (1)
[New applications of erythropoietin in cardiovascular disease: from haematopoiesis to cardiac protection]. (2008) (1)
[Beta-blocking drugs indicated in patients with heart failure]. (2003) (1)
The Nobel Prize for medicine for telomere biology and relevance to heart failure research. (2009) (1)
[Cardiac rehabilitation in patients with a congenital heart disease, an implantable cardioverter defibrillator or chronic heart failure]. (2004) (1)
Discussion forum response to Canepa et al. (2018) (1)
Dilated cardiomyopathy complicates pregnancy outcome: but how? (2010) (1)
Erratum to: Galectin-3 in Cardiac Remodeling and Heart Failure (2012) (1)
ATTR Amyloidosis: development of cardiac symptoms during 6 years of follow up in different ATTR-variants (2015) (1)
Heart failure management: how much COACH-ing is needed? (2005) (1)
[Cardiogenetics: the importance of identifying patients with hereditary heart disease]. (2007) (1)
Effects of epanolol, a selective beta1-blocker with intrinsic sympathomimetic activity, in patients with ischemic left ventricular dysfunction. (1998) (1)
Images in cardiology. Rapid progression of pericardial malignant mesothelioma. (1998) (1)
Data Sharing From the Editors' Perspective: Our Hope With Limitations. (2017) (1)
Patients with heart failure with and without a history of stroke in the Netherlands: a secondary analysis of psychosocial, behavioural and clinical outcomes up to three years from the COACH trial (2019) (1)
Cerebroprotective effects of angiotensin II (AT 1) receptor antagonists? (2005) (1)
Effects of mineralocorticoid receptor antagonists in HFrEF patients with COPD in EMPHASIS-HF and RALES. (2021) (1)
[Value of basic and intensive management of patients with heart failure; results of a randomised controlled clinical trial]. (2008) (1)
Diuretic therapy as prognostic enrichment factor for clinical trials in patients with heart failure with reduced ejection fraction (2021) (1)
Achieving appropriate endpoints in heart failure trials: the PRIME‐II protocol (1999) (1)
Heart failure: chapter 6. Pharmacological treatment of chronic heart failure. (2004) (1)
Effects of Eprosartan on Diastolic Function and Neurohormones in Patients with Hypertension and Diastolic Dysfunction (2010) (1)
[Experiences of combined heart-lung transplantations in the University Medical Center Groningen]. (2009) (1)
Sex differences in associations of comorbidities with incident cardiovascular disease: focus on absolute risk (2022) (1)
Heart matters: cardiovascular complications related to cancer treatment. (2013) (1)
Author Correction: Causal Pathways from Blood Pressure to Larger QRS Amplitudes: a Mendelian Randomization Study (2018) (1)
Sexual dimorphism in selenium deficiency is associated with metabolic syndrome and prevalence of heart disease (2023) (1)
1242: Coordinating Study Evaluating Outcomes of Advising and Counselling in Heart Failure (COACH): Methodology and Design (2003) (1)
Heart Failure and Pancreas Exocrine Insufficiency: Pathophysiological Mechanisms and Clinical Point of View (2022) (1)
Adherence to guidelines is a predictor of outcome in chronic heart failure: the MAHLER survey. (2005) (1)
Long-term outcome after heart transplantation performed in the University Medical Centre Groningen. (2006) (1)
[Implantable cardioverter-defibrillator in the treatment of two patients with an increased risk of sudden cardiac death]. (2004) (1)
Implantable cardioverter-defibrillators. (2005) (1)
Implication from Randomized Trials of Rate and Rhythm Controls on Management of Patients with Persistent Atrial Fibrillation (2006) (1)
The European Journal of Heart Failure from 2010 to 2015 (2014) (0)
Current insights and new treatment options in heart failure. (1998) (0)
128 Clinical impact of changes in mitral regurgitation severity after optimization of medical therapy in heart failure: insights from BIOSTAT-CHF (2021) (0)
1473 Treatment Related Caregiving Demands of Partners of HF Patients (2005) (0)
Using matrix assisted laser desorption ionisation mass spectrometry (MALDI-MS) profiling in order to predict clinical outcomes of patients with heart failure (2018) (0)
[Non-pharmacological treatment of heart failure: implantable cardioverter defibrillator (ICD) and cardiac resynchronisation therapy]. (2006) (0)
1474 Need for Information Concerning Sexual Changes in Chronic Heart Failure Patients (2005) (0)
Galectin-3, acute kidney injury and myocardial damage in patients with acute heart failure. (2022) (0)
[Digoxin in chronic heart failure and sinus rhythm: is the end of the controversy in sight?]. (1997) (0)
Additive value of transoesophageal echocardiography in the visualization of carcinoid heart disease. (1992) (0)
192 Poster Quality of Life in Heart Failure Patients with Preserved Ejection Fraction is Worse than in Heart Failure Patients with Reduced Ejection Fraction (2010) (0)
[Effect of aldosterone antagonism in heart failure: pharmacotherapeutic options]. (2001) (0)
Long-term outcome of targeted therapy of underlying conditions in patients with early persistent atrial fibrillation and heart failure: data of the RACE 3 trial (2021) (0)
Reply: To PMID 23500300. (2013) (0)
Optimal imaging of patients with ischaemic heart failure (2006) (0)
Differential anti-ischaemic effects of muscarinic receptor blockade in patients with obstructive coronary artery disease; impaired vs normal left ventricular function. (1999) (0)
From normal to Mahaim to Ebstein electrocardiogram. (2003) (0)
1480 Why do Heart Failure Patients not Comply with Diet, Fluid Restriction and Daily Weighing? (2005) (0)
Predictors of adverse diastolic remodeling in non-diabetic patients presenting with ST-elevation myocardial infarction (2023) (0)
[Life-threatening ventricular tachycardia during flecainide treatment for symptomatic atrial fibrillation in a patient with a structural cardiac disorder]. (2006) (0)
Right‐heart dysfunction in women with congenital heart disease and pre‐eclampsia (2022) (0)
[Revised insights and therapeutic goals in the treatment of chronic heart failure]. (1999) (0)
Systemic oxidative stress associates with disease severity and outcome in patients with new-onset or worsening heart failure (2023) (0)
[Successful heart transplantation in long-term ventilated patients]. (1996) (0)
[Treatment of Angina pectoris using nitrates]. (1996) (0)
Implications of worsening renal function before hospitalization for acute heart failure (2022) (0)
Clinical and prognostic associations of autoantibodies recognizing adrenergic/muscarinic receptors in patients with heart failure. (2023) (0)
Treating Microalbuminuria-Cosmetic Exercises with Urine Chemistry or Effective Reduction of Clinical Events?: Effects of Fosinopril and Pravastatin on Cardiovascular Events in Subjects with Microalbuminuria. Circulation 110: 2809-2816, 2004. (2005) (0)
Perceived risk profile and treatment optimization in heart failure: an analysis from BIOlogy Study to TAilored Treatment in chronic heart failure (2021) (0)
Quality of life in patients with preserved and depressed left ventricular function. (2005) (0)
Profile: Dirk J. van Veldhuisen, professor and chairman of cardiology at the University Medical Centre, Groningen, Netherlands. (2013) (0)
1398: Anaemia and renal function independently associated with N-terminal pro B-type natriuretic peptide in patients hospitalised for heart failure: comparison with B-type natriuretic peptide (2006) (0)
Causal Pathways from Blood Pressure to Larger QRS Amplitudes: a Mendelian Randomization Study (2018) (0)
Application form based optimization of the echo lab workflow (2002) (0)
Anemia and congestive heart failure. (2003) (0)
Exercise: integral part in the multidisciplinary approach to heart failure management? (2004) (0)
The influence of body mass index on clinical interpretation of established and novel biomarkers in acute heart failure. (2023) (0)
Pro‐gastrin‐releasing peptide and outcome in patients with heart failure and anaemia: results from the RED‐HF study (2018) (0)
Author Correction: Causal Pathways from Blood Pressure to Larger QRS Amplitudes: a Mendelian Randomization Study (2018) (0)
Searching for dose-response in HF clinics. (2004) (0)
1309: Relationship Between B-Type Natriuretic Peptide and 6 Min Walk in Chronic Heart Failure (2004) (0)
Anemia and erythropoietin in heart failure. (2008) (0)
Underestimation of circulatory congestion in very obese HFpEF patients: EAT your heart out..?! (2021) (0)
Beta-blockade in chronic heart failure. (2001) (0)
Abstract 11150: Albuminuria in Heart Failure is More Strongly Associated with Markers of Congestion Than Renal Dysfunction (2021) (0)
Oral ibopamine substitution in patients with intravenous dopamine dependence. (1995) (0)
Dose-limiting, adverse event–associated bradycardia with β-blocker treatment of atrial fibrillation in the GENETIC-AF trial (2021) (0)
Alternating bundle branch block. (2002) (0)
[Treatment of hypertension: angiotensin-II antagonists potentially better than beta-blockers in the occurrence of cardiovascular and cerebrovascular damage; the LIFE study in perspective]. (2003) (0)
[Addition of beta blockers in chronic heart failure]. (2000) (0)
Pregnancy unbosoms the heart of breast cancer survivors. (2012) (0)
Value of simultaneous monitoring of right ventricular oxygen saturation and pressure using biosensors. (1995) (0)
Myocardial HER2 expression with 111In-DTPA-trastuzmab scan in patients shortly after anthracycline treatment. (2006) (0)
Biomarker changes as surrogate endpoints in early‐phase trials in heart failure with reduced ejection fraction (2022) (0)
Associations of relative fat mass, a new index of adiposity, with type-2 diabetes in the general population. (2023) (0)
1317: Compliance with Diet, Fluid Restriction and Daily Weighing in Heart Failure Patients (2004) (0)
Urinary Marker Profiles in Heart Failure with Reduced Versus Preserved Ejection Fraction. (2023) (0)
Atrial fibrillation is more troublesome in heart failure patients with preserved compared to those with reduced ejection fraction. (2018) (0)
Ischaemia in heart failure with preserved ejection fraction; is it important? (2016) (0)
The electrocardiogram in traumatic right atrial rupture. (1999) (0)
Relative fat mass, a new index of adiposity, is strongly associated with incident heart failure: data from PREVEND (2022) (0)
Diffuse Myocardial Fibrosis on Cardiac Magnetic Resonance Imaging Is Related to Galectin-3 and Predicts Outcome in Heart Failure (2023) (0)
Heart failure with normal LVEF in BIOSTAT-CHF. (2022) (0)
Treatment of mild heart failure: the place of diuretics and ibopamine. (1997) (0)
Digitalis in heart failure: declining use and ongoing outcome trials. (2023) (0)
More evidence in favour of early blockade of the renin-angiotensin system. (2002) (0)
Heart rate in patients with atrial fibrillation and heart failure with preserved ejection fraction: a prognosticator like in sinus rhythm? (2019) (0)
Correction to: The influence of atrial fibrillation on the levels of NT-proBNP versus GDF-15 in patients with heart failure (2020) (0)
1302: Heart Failure Programs and the Heart Failure Nurse in the Netherlands (2004) (0)
Assessment of Proximal Tubular Function by Tubular Maximum Phosphate Reabsorption Capacity in Heart Failure (2022) (0)
A pilot study on the effect of advance care planning implementation on healthcare utilisation and satisfaction in patients with advanced heart failure (2022) (0)
The dimension of 2D and 3D Poincare plots obtained from 24 hour ECG registrations (2002) (0)
1346: Quality of Life and Marital Status in HF Patients (2004) (0)
Transitions across Kidney Disease Stages and Association with New-onset Heart Failure: a Population-Based study of 8569 Individuals and 12.6 Years of Follow-up (2023) (0)
FMMP9 A New Episode of Depressive Symptoms is Related to all Cause Readmission in Patients with Heart Failure (2009) (0)
Dirk J. van Veldhuisen, outgoing Editor-in-Chief of the European Journal of Heart Failure (EJHF), discusses some of the highlights and challenges of the last 5 years, with Judy Ozkan MA. (2013) (0)
Awareness of atrial fibrogenesis and natriuretic peptide release (2017) (0)
1345: Heart Failure Patients and their Social Context (2004) (0)
[Dobutamine therapy at home under the guidance of a nurse practitioner, either as a bridge to cardiac transplantation or as destination therapy in severe heart failure]. (2007) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Dirk Jan Van Veldhuisen?

Dirk Jan Van Veldhuisen is affiliated with the following schools:

Université libre de Bruxelles
University of Groningen